Podcasts about enbrel

From compromised vaccines to failed clinical trials, the stakes of biopharma cold chain failures are dangerously high. Each year, the industry loses $35 billion due to temperature excursions and environmental deviations in transit. But the cost to patient safety? Incalculable.In this episode, we examine the hidden weak points in cold chain logistics and why manual processes and siloed systems are no longer acceptable. Drawing from The cold truth: Why biopharma needs integrated cold chain monitoring tech, we uncover how IoT devices, smart packaging, and ERP-integrated platforms are transforming temperature-sensitive logistics—from warehouse to drone-based last-mile delivery.What You'll Learn in This Episode:1. The Hidden Cost of Cold Chain Failures$35B in annual losses from temperature excursions and environmental mishandling20% of pharma products are damaged by temperature issues aloneNearly half of surveyed companies experience multiple excursions yearly2. Why ‘Almost Perfect' Isn't Good EnoughMany advanced therapies use a stability budget—once it's gone, efficacy is lostSome products (e.g., Humira, Enbrel) must avoid both overheating and freezingVibration and humidity sensitivity add even more complexity3. The Limits of Manual & Legacy SystemsFragmented cold chains and outdated spreadsheets lack end-to-end visibilitySome companies still do not consistently use basic temperature monitoringRegulatory compliance requires verifiable, real-time control4. Integrated Tech as the New StandardSmart tags, RFID, and IoT devices feed data into centralized ERP systemsReal-time monitoring of temperature, vibration, humidity, and TORPredictive alerts and proactive interventions reduce spoilage risk5. The Future of Cold Chain LogisticsAdoption of TOR-based warehouse picking strategiesDeployment of agentic AI for self-optimizing logisticsProof-of-concept drone delivery of ultra-cold products (e.g., -70°C) by MerckShift toward reusable thermal containers and TCO-driven decision-makingKey Takeaways:Cold chain integrity is critical for both product viability and patient safetyIntegrated monitoring platforms provide provable control—essential for complianceCompanies adopting these solutions have cut losses by up to 20%The rise of agentic AI and real-time monitoring marks a new era in biopharma logisticsGlobal regulations must evolve to keep pace with tech and therapeutic complexitySubscribe to our podcast for expert insights on supply chain innovation, life sciences logistics, and pharmaceutical compliance. Visit The Future of Commerce for the latest on how tech is transforming healthcare delivery. Share this episode with supply chain leaders, pharma execs, and regulatory professionals.

This Day in Legal History: President Lincoln DiesOn this day in legal history, April 15, 1865, President Abraham Lincoln died from a gunshot wound inflicted the night before by actor and Confederate sympathizer John Wilkes Booth. The assassination occurred at Ford's Theatre in Washington, D.C., where Lincoln was watching a play with his wife. He was shot in the back of the head and never regained consciousness, dying the next morning at 7:22 a.m. His death was the first assassination of a U.S. president and triggered a constitutional transition of power during a critical moment in American history. Vice President Andrew Johnson was sworn in the same day, inheriting the enormous task of leading the country through the fragile early stages of Reconstruction.Legally, Lincoln's assassination set several precedents. It led to the use of military tribunals to try civilians involved in Booth's conspiracy, a decision that remains controversial in constitutional law. The event also underscored the importance of presidential succession, later clarified by the 25th Amendment. In the immediate aftermath, martial law and curfews were imposed in the capital, and a massive manhunt ensued for Booth and his co-conspirators. The killing intensified public sentiment against the South and complicated efforts to reunify the nation. Johnson's approach to Reconstruction diverged sharply from Lincoln's more conciliatory plans, shaping decades of legal and political conflict over civil rights. The assassination deeply impacted how the federal government approached both national security and executive protection. The tragedy marked not just the loss of a president, but a shift in the legal and political structure of post-Civil War America.As Lincoln's funeral train retraced the route that had carried him from obscurity in Illinois to the presidency, it served as a symbolic farewell to both the man and the future he might have shaped. Each stop along the way—cities draped in mourning, crowds in silent grief—marked not only the end of his political journey but also the shunting off of a potential trajectory for his second term. Had Lincoln lived, his vision for a more lenient and reconciliatory Reconstruction might have softened the bitter divisions that would later deepen under Andrew Johnson's combative leadership. Perhaps civil rights protections would have been implemented sooner, with Lincoln using his political capital and moral authority to push for more lasting equality. The possibility remains that a different course could have been taken—one that prioritized unity without compromising justice, and that may have led to a more inclusive and less violent post-war America.Kilmar Abrego Garcia, a legally residing Salvadoran migrant in Maryland with a U.S. work permit, was wrongly deported to El Salvador in March, despite a judge's order blocking his removal. The Trump administration acknowledged the deportation was in error but has told a federal court it is not obligated to help him return from prison in El Salvador, interpreting a Supreme Court directive to "facilitate" his return as limited to removing domestic barriers—not assisting with his release abroad. A U.S. District Court judge had ordered the government to bring him back, a decision the Supreme Court upheld by rejecting the administration's appeal. However, a top immigration official has now argued the deportation order is moot, citing Abrego Garcia's alleged ties to MS-13, a group newly designated as a foreign terrorist organization. The State Department has confirmed that Abrego Garcia is "alive and secure" in a terrorism detention facility in El Salvador. Legal efforts continue, with Abrego Garcia's attorneys seeking more information from the government. The administration warns this could disrupt diplomatic talks, particularly with El Salvador's President Nayib Bukele visiting Washington. President Trump has said his administration would comply if ordered directly by the Supreme Court.Trump administration says it is not required to help wrongly deported man return to US | ReutersSandoz, a Swiss generic drugmaker, has filed a U.S. antitrust lawsuit against Amgen, accusing it of unlawfully maintaining a monopoly on its arthritis drug Enbrel. The lawsuit, filed in federal court in Norfolk, Virginia, alleges that Amgen created a "thicket of patents" to block the entry of biosimilar competitors like Sandoz's Erelzi, which has been approved by the FDA since 2016 but has not launched in the U.S. Sandoz claims this strategy has kept its lower-cost alternative off the market, depriving patients of affordable options and causing the company to lose millions in potential monthly sales. Amgen has not yet commented on the lawsuit. Enbrel generated $3.3 billion in U.S. revenue in 2024 alone and is used to treat inflammatory diseases such as rheumatoid arthritis. Sandoz argues that Amgen's patent practices violate federal antitrust laws by suppressing competition and artificially extending its market dominance. The company is seeking an injunction to stop Amgen from using its patent portfolio in this way, as well as financial damages for lost sales.Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug | ReutersThe U.S. Government Accountability Office (GAO) has agreed to investigate recent changes at the Securities and Exchange Commission (SEC), including those influenced by the White House and the Department of Government Efficiency (DGE), led by Elon Musk. This probe follows a request from Senators Elizabeth Warren and Mark Warner, who raised concerns about the SEC's ability to fulfill its regulatory duties amid sweeping restructuring efforts. Since President Trump's return to office and the Republican takeover of the agency, the SEC has reduced staff, ended leases, and reorganized operations. It has also scaled back enforcement efforts and seen a wave of resignations as part of a broader federal downsizing initiative. The GAO confirmed that the request for an investigation falls within its authority, with the review expected to begin in about three months. Lawmakers stress the importance of understanding how these changes may be undermining the SEC's mission. The agency's funding, while approved by Congress, is sourced from transaction fees rather than taxpayer dollars. These developments coincide with market instability triggered by Trump's recent tariff announcement.US congressional watchdog to probe changes at the SEC, letter says | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Mike is an IT Infrastructure Manager in Las Vegas, and he's coming up on 1 year of Carnivore in March. He was diagnosed with Mixed Connective Tissue disorder in 2016, and has in the past been on Methotrexate, Prednisone, Enbrel, and Rinvoq. MCTD consists of elements of Sjogens, Rheumatoid Arthritis, and Lupus. Since going Carnivore, the only non-Carnivore thing he still uses that helps is Qunol Tumeric and Ginger gummies to help with inflammation. He has lost 50 pounds, his symptoms are gone until he eats something he shouldn't, and he has more energy and his hands have stopped hurting. Timestamps: 00:00 Trailer 01:18 Introduction 07:49 Sedentary job, unhealthy diet 08:58 Loss of basic functionality 13:34 Keto diet success and weight loss 16:06 Beef-centric meal prep routine 18:35 Rib eye diet cures symptoms 22:30 Couple's weight loss success 24:40 Prioritizing quality meats over extras 29:38 Diet's role in rheumatism neglected 31:43 Air fried rib eyes & snacks 35:06 Curbing cravings with ribeye 38:15 Revitalizing lives through dietary change 40:45 Easing into a carnivore diet 43:10 Mindful eating on vacation 46:34 Where to find Mike Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

In this episode of Let's Talk Future, Joel Sendek and Matt Biegler discuss the use of CAR T-cell therapy in autoimmune indications. They explain that CAR T-cell therapy involves modifying a patient's T cells to recognize and fight cancer cells. While CAR T-cell therapy has been successful in treating certain types of cancer, its application in autoimmune diseases is still in the early stages. Matt Biegler highlights the challenges and potential modifications needed for CAR T-cell therapy to be effective in autoimmune diseases. They also discuss the companies involved in developing CAR T-cell therapies for autoimmune indications and the potential market size for these treatments.   Podcast Disclosure: This podcast is the property of Oppenheimer & Co. Inc. and should not be copied, distributed, published or reproduced, in whole or in part. The information/commentary contained in this recording was obtained from market conditions and professional sources, and is educational in nature. The information presented has been derived from sources believed to be reliable but is not guaranteed as to accuracy and does not purport to be a complete analysis of any strategy, plan, security, company, or industry involved. Opinions expressed herein are subject to change without notice. Oppenheimer has no obligation to provide any updates or changes. Any examples used in this material are generic, hypothetical and for illustration purposes only. All price references and market forecasts are as of the date of recording. This podcast is not a product of Oppenheimer Research, nor does it provide any financial, economic, legal, accounting, or tax advice or recommendations. Any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. Securities and other financial instruments that may be discussed in this report or recommended or sold are not insured by the Federal Deposit Insurance Corporation and are not deposits or obligations of any insured depository institution. Investments involve numerous risks including market risk, counterparty default risk and liquidity risk. Securities and other financial investments at times maybe difficult to value or sell. The value of financial instruments may fluctuate, and investors may lose their entire principal investment. Prior to making any investment or financial decisions, an investor should seek advice from their personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. The views and strategies described may not be suitable for all investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer or its affiliates. This presentation may contain forward looking statements or projections regarding future events.  Forward-looking statements and projections are based on the opinions and estimates of Oppenheimer as of the date of this podcast, and are subject to a variety of risks and uncertainties as well as other factors, including economic, political, and public health factors, that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and projections.  Past performance does not guarantee future results. The performance of a benchmark index is not indicative of the performance of any particular investment; however, they are considered representative of their respective market segments.  Please note that indexes are unmanaged and their returns do not take into account any of the costs associated with buying and selling individual securities.  Individuals cannot invest directly in an index. Humira, manufactured by AbbVie and Enbrel, manufactured by Amgen, are not covered by Oppenheimer Research Oppenheimer Transacts Business on all Principal Exchanges and Member SIPC 6840494.1

Dr. Ira Spector, PhD is CEO and a Co-Founder of SFA Therapeutics ( https://sfatherapeutics.com/ ), a microbiome-derived biopharma company focused on new advancements in the treatment inflammatory diseases. Dr. Spector is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Development. At Allergan, Dr. Spector helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Prior to Wyeth, he was Vice President and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Dr. Spector was Executive Vice President of Analytics & Consulting at ICON. Dr. Spector holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD in Health Sciences from UMDNJ. Support the show

Rosemary also shares her experience with a mystery skin rash that ended up being a rare psoriatic arthritis medication side effect: leukocytoclastic vasculitis triggered by drug-induced lupus, and an eventual diagnosis of Palisaded Neutrophilic and Granulomatous Dermatitis. Throughout the episode, Rosemary and Cheryl discuss the importance of coping skills for difficult medical experiences. They also emphasize the importance of finding the right medications, lifestyle strategies, and the role of psychosocial support. Uncertainty and setbacks can be overwhelming, but self-compassion, support systems, acceptance, and perseverance can help you pursue a fulfilling life despite health challenges.Episode at a glance:Chronic Illness Journey: The interview delves into Emily's journey of living with chronic illnesses, from psoriatic arthritis, to developing drug-induced lupus which triggered leukocytoclastic vasculitis, and eventually being diagnosed with Palisaded Neutrophilic and Granulomatous Dermatitis (PNGD).Medication Management: Rosemary shares her experiences with various medications, including Enbrel, Humira, and Plaquenil, discussing their effectiveness in managing her symptoms and the decision-making process involved in discontinuing certain medications. They discuss the importance in recognizing adverse effects, while balancing this understanding with the benefits that medications do provide.Lifestyle strategies: Rosemary emphasizes the importance of physical activity and wellness in her life, despite her health challenges.Emotional Resilience: Navigating the emotional highs and lows with chronic illness can be overwhelming, from the initial relief of finding treatments to the grief and uncertainty of adjusting plans. Cheryl and Rosemary discuss self-advocacy, and pursuing fulfilling lives despite obstacles .Adapting to Change: Rosemary and Cheryl discuss how to adapt to change, both in terms of treatment plans and mindset towards living with chronic illness, including exploring alternative treatments and embracing new perspectives.Support: Rosemary reflects on the role of support from healthcare providers, online support groups, and in personal relationships - underscoring the importance of having a strong network when facing chronic illness.Advice to Newly Diagnosed Patients: “You don't have control of the fact that that happened to you, and you didn't do anything wrong. All you can do now is choose how to react to it. Do the next right thing. Little by little by little, it'll start coming together. And you're going to be okay.”Medical disclaimer: All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now! For full episode details including a transcriptGo to the episode page on the Arthritis Life Website (transcript coming soon!).

Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.'s negative US FDA advisory committee decision on its ALS drug (:43), the impact of a government shutdown on the agency (10:00), and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations (22:58). More On These Topics From The Pink Sheet BrainStorm's NurOwn Gets Many, Many Thumbs Down From US FDA Panel: https://pink.citeline.com/PS148915/BrainStorms-NurOwn-Gets-Many-Many-Thumbs-Down-From-US-FDA-Panel Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees: https://pink.citeline.com/PS148923/Preparing-For-A-Shutdown-US-FDA-To-Retain-81-Of-Workforce-Thanks-Mostly-To-User-Fees Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions: https://pink.citeline.com/PS148917/Republican-Lawmaker-Takes-Unusual-Step-Of-Attacking-FDA-Salaries-Over-Abortion-Pill-Decisions Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round: https://pink.citeline.com/PS148916/Imbruvica-Enbrel-Stelara-Offer-Best-Chance-Of-Savings-From-Medicare-Negotiation-In-First-Round

The federal government announced it has selected the first 10 drugs it will negotiate for lower prices with pharmaceutical firms. The Centers for Medicare and Medicaid Services selected the drugs, all of which are covered under Medicare Part D. The 10 drugs — Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog — accounted for .5 billion of total costs for Medicare's Part D program from June 2022 to May 2023. Medicare plans to use the cost savings to place a ,000 limit on enrollees' of out-of-pocket expenditures for drugs starting in 2026. But it could delay innovation...Article Link

Mark Twain once said, “Never put off till tomorrow, what you can do the day after tomorrow.” As an antidote to that Ralph welcomes Professor Piers Steel, author of “The Procrastination Equation: How to Stop Putting Things Off and Start Getting Stuff Done.” Plus, Ralph urges listeners to sign up for The Capitol Hill Citizen Association, another way to organize citizens to put pressure on the branch of our government where things must get done, the United States Congress.  Dr. Piers Steel is one of the world's leading researchers and speakers on the science of motivation and procrastination. Dr. Steel is a professor in the Organizational Behaviour and Human Resources area at the University of Calgary, and is the Brookfield Research Chair at the Haskayne School of Business. He is the author of The Procrastination Equation: How to Stop Putting Things Off and Start Getting Stuff Done.The root of procrastination is impulsiveness. Impulsiveness is valuing the now more than the later… We're designed to value the now. And this was really adaptive for a long time. It's not a bad trait. It's just that we've designed a world to take advantage of every little flaw that we have in our decision-making system.Dr. Piers SteelYou have to deal with yourself as an imperfect, flawed creature and deal with the reality of that. We're not robotic angels of perfection. We have limitations. And when I actually act within my limitations, I get stuff done.Dr. Piers SteelWe're superstars of self-control in the animal kingdom. We're able to hunt and kill most anything because we're willing to actually put in the delay of gratification. That's really what makes us great. But we're still not ready for things that are happening even a year off, much less five or ten.Dr. Piers SteelMore people will listen to what we just said about becoming part of the Capitol Hill Citizen Association and say to themselves, “I'm going to get around to doing that,” than the actual number of people who do it in a prompt period of time. So it would be very good to listen to Professor Steel's suggestions and read his book, because we cannot afford procrastinatory citizens. We have a procrastinatory Congress, and the citizens have got to get them to anticipate, to foresee, to forestall so many of the omnicidal urgencies that are coming at our country and other countries around the world.Ralph NaderTo become a member of the Capitol Hill Citizen Association, click here.In Case You Haven't Heard with Francesco DeSantis1. On August 28th, 20 groups – ranging from Left-wing anti-war organizations like Veterans for Peace to Right-leaning government transparency groups like R Street Institute – sent a letter to the Chairs and Ranking Members of the House and Senate Armed Services Committees demanding they maintain Rep. Jamaal Bowman's Cost of War amendment in the final National Defense Authorization Act. This provision “requires public disclosure about the cost of the U.S.' overseas military footprint and gives the American people greater transparency on military spending.” Hopefully, the left-right consensus on this issue is enough to maintain this amendment.2. In other Pentagon news, the Intercept reports that Rep. Matt Gaetz, Republican of Florida, has introduced an amendment demanding the Pentagon “collect information on trainees who overthrow their governments,” following the recent spate of coups in Africa. Gaetz told the Intercept “The Department of Defense, up until this point, has not kept data regarding the people they train who participate in coups to overthrow democratically elected — or any — governments.” This could become a flashpoint as Congress prepares to consider the 2024 NDAA when it returns from recess in September.3. As expected, tensions are running high in Guatemala following the upset victory of anti-corruption crusader Bernardo Arevalo. Opponents of Arevalo had urged the country's electoral tribunal to suspend his Semilla party on dubious legal grounds, which the tribunal resisted hewing to the letter of the law which dictated such actions could not be taken during the electoral process. After the election however, the party was officially suspended. Now, Reuters reports that suspension has been revoked, following a mass mobilization of Arevalo supporters in Guatemala City. It seems unlikely however that Arevalo's political opponents will accept his victory without a fight.4. In a dangerous, anti-free speech move, the Attorney General of Georgia has filed RICO indictments against 42 individuals involved with the Stop Cop City protest movement, the Atlanta Community Press Collective reports. This is the latest in a long line of attempts to quash opposition to the project, which has so far included trumped up domestic terrorism charges and arrests for handing out flyers.  5. Bloomberg reports that President Biden and Brazilian President Lula will jointly call for new worker protections at the upcoming General Assembly of the United Nations. While the article notes the two leaders have been “at odds” over China and Russia, they align on the topic of labor unionization. The two presidents have found common ground before, such as on the issue of climate change.6. Visual Effects workers at Disney have filed for unionization, per the Hollywood Reporter. Approximately 80% of VFX staff have already signed union cards, demanding an NLRB election and representation by the International Alliance of Theatrical Stage Employees or IATSE. This comes on the heels of a similar announcement by VFX workers at Marvel, a Disney subsidiary. In recent years. studios have increasingly relied on VFX workers in a rather blatant attempt to cut costs, as VFX workers have generally been non-union.7. At long last, the Department of Health and Human Services has announced the first ten drugs that will be subject to Mecicare negotiations to bring down prices. These are: Eliquis, Jardiance, Xarelto, Januvia Farxiga, Entresto, Enbrel, Imbruvica, Stelara and – crucially – several brands of insulin. HHS noted that “These selected drugs accounted for $50.5 billion in total [Medicare] Part D gross covered prescription drug costs, or about 20%, of total Part D gross between June 1, 2022 and May 31, 2023.”8. The Washington Post reports Acting Labor Secretary Julie Su has proposed new overtime rules intended to “extend overtime pay to an additional 3.6 million salaried white-collar workers in the United States.” According to current rules, workers are exempt from overtime if they make over $35,568 per year; the new rules would extend to workers making under $55,000 annually. If implemented, this would mean a whole new class of workers would be eligible for time-and-a-half pay if they work more than 40 hours per week.9. Per Republic Report: “The U.S. Department of Education announced…that it is cancelling $72 million in student loan obligations for more than 2,300 former students who attended for-profit Ashford University between 2009 and 2020.” Yet, even now the shady operators behind Ashford may still be able to squeeze money out of the taxpayers via a convoluted buyout by the University of Arizona Global Campus. Still, this marks a significant victory in a legal battle that has raged for over a decade, with Senator Tom Harkin of Iowa calling Ashford a “complete scam” all the way back in 2011.10. Finally, in more debt related news, the Philadelphia Inquirer has published a piece detailing how the nonprofit RIP Medical Debt was able to purchase – and forgive – over $1.6 million in medical debt. As the piece explains “When hospitals or physician groups have delinquent debts they have little chance of collecting on, they'll typically go to what's called the secondary market and sell their portfolios for pennies on the dollar.” It was on this secondary market that RIP Medical Debt was able to buy $1.6 million worth of debt for just $17,000. In celebration, “30 proud, self-described gutter-pagan, mostly queer dirtbags in their early 30s,” gathered for a ritual burning of an oversized medical bill. Someone chanted “debt is hell” and the crowd responded “let it burn.” Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

Politisches Risiko und hoch im Kurs Wer meine Podcasts Börsenminute und GELDMEISTERIN schon länger verfolgt, weiß, dass ich Pharmaaktien für mein Langfristportfolio als eine wichtige Säule favorisiere und das tue ich auch weiterhin. Nur: durch die letzten starken Anstiege vor allem beim skandinavischen Shootingstar Novo Nordisk (Stichwort Diabetesmedikamente, die als Abnehmpille Furore machen) bin ich dabei, mein Pharma-Portfolio zu Rebalancieren, sprich einen Teil der Kursraketen zu verkaufen, um den Gesundheitstitel-Anteil und so mein Klumpenrisiko wieder zu reduzieren. Oder mir maximal die jüngsten Rohrkrepierer wie Roche zumindest genauer anzuschauen. Denn Risiko-behaftet sind Gesundheitstitel in jedem Fall und da denke ich nicht einmal an etwaige Nebenwirkungen, die in der Vergangenheit schon des Öfteren zu sündteuren Klagen geführt haben. Nein, es sind die Bewertungen, die ich teilweise nicht mehr gesund finde. Eli Lilly zum Beispiel hat in den letzten fünf Jahren um 430 Prozent zugelegt. Das Kurs-Gewinn-Verhältnis liegt bei knapp 56. Soll heißen, ich muss - aus heutiger Sicht wohlgemerkt - 56 Jahre warten, bis ich den Preis für die Aktie hereinverdient habe. Das dauert mir zu lange, auch wenn ich ihnen viel Gewinnsteigerungspotenzial noch zutraue. Man sollte keinesfalls das politische Risiko der Branche unterschätzen. Joe Biden hat gerade zehn Medikamente auf seiner Watchlist, die seinen „Inflation Reduction Act“ konterkarieren. Hier wird gerade mit Bristol-Myers, Johnson & Johnsohn, Merck, Novo Nordisk, Boehringer Ingelheim, Novartis, Amgen & Co gefeilscht, welche Preise das staatliche Gesundheitssystem künftig nur noch für die Arznei bereit ist zu bezahlen und das ist nicht unerheblich. Zum einen, schreibt die Financial Times, droht ihnen eine Besteuerung von 65 bis 95 Prozent, zum anderen ein Ausschluss aus dem Gesundheitsprogramm Medicare, was tragisch wäre, da es teilweise zu 50 Prozent ihre Umsätze in den USA sichert. Die konkreten Medikamente, deren Preise für Biden´s Geschmack zu hoch sind, findet ihr hier im Beipackzettel zu dieser Börsenminute: • Eliquis von Bristol-Myers Squibb (NYSE:BMY); • Jardiance von Boehringer Ingelheim; • Xarelto von Johnson & Johnson (NYSE:JNJ); • Januvia von Merck (NYSE:MRK); • Farxiga von AstraZeneca (NASDAQ:AZN); • Entresto von Novartis (NYSE:NVS); • Enbrel von Amgen (NASDAQ:AMGN); • Imbruvica von AbbVie (NYSE:ABBV); • Stelara von Janssen (im Besitz von JNJ); • Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill von Novo Nordisk (NYSE:NVO). Rechtshinweis: Dies ist die Meinunung der Autorin und keine Anlageempfehlung. Was ihr daraus macht ist Eure Sache, Julia Kistner übernimmt hierfür keine Haftung. #Börse #investment #Pharmatitel #Inflationreductionact #Aktien #podcast Foto: Unsplash

Florida Gov and GOP 2024 also-ran Ron DeSantis looks to lead in wake of violence and major hurricane | Former SC Gov and UN Ambassador under President Trump, Nikki Haley is having a moment, kind of | President Biden names first 10 drugs subject to negotations with Medicare | 60th anniversary of the March on WashingtonSong playsIntro by hostWelcome to Heartland Pod Wednesday!Support this show and all the work in the Heartland POD universe by going to heartlandpod.com and clicking the link for Patreon, or go to Patreon.com/HeartlandPod to sign up. Membership starts at $1/month, with even more extra shows and special access at the higher levels. No matter the level you choose, your membership helps us create these independent shows as we work together to change the conversation.Alright! Let's get into it: Hurricane in Florida / Shooting in FloridaPOLITICO: DeSantis knows how to handle a hurricane. The racist shooting poses a bigger dilemma.A racially-motivated Jacksonville tragedy, couple with a looming storm, pose big tests for the governor.Florida Gov. Ron DeSantis, center and his wife Casey, right, bow their heads during a prayer.Florida Gov. Ron DeSantis (center) and his wife Casey bow their heads during a prayer at a vigil for the victims of Saturday's mass shooting on Sunday, Aug. 27, 2023, in Jacksonville. | John Raoux/AP PhotoBy KIMBERLY LEONARD08/28/2023 04:14 PM EDTUpdated: 08/28/2023 05:12 PM EDTMIAMI — Florida Gov. Ron DeSantis' handling of back-to-back crises — a racist mass shooting and a potentially catastrophic hurricane — could help burnish his image as a can-do, effective governor or further damage his standing with Black Americans who have grown livid over his policies.Already, DeSantis' attempts to show leadership in the immediate aftermath of the Saturday shooting were poorly received by some Black lawmakers, Democrats and residents in Florida. In the hours after a 21-year-old white man killed three Black Floridians near a historically Black college in Jacksonville, several state Democrats blamed DeSantis, who is running for president, for creating an environment, through policies such as loosening gun laws and ending diversity programs, that helped hate fester.DeSantis has condemned the shooting and said “targeting people due to their race has no place in this state of Florida.” But attending a Sunday night vigil in Jacksonville, he was jeered and booed by people who had come out to remember the victims. At one point, a Jacksonville Democratic councilmember stepped in to calm the crowd, urging people to “put parties aside.” Later during the event, a pastor took issue with DeSantis describing the gunman as a “scumbag,” and said he should have used the word “racist” instead.The vigil stood in contrast to press conferences in Tallahassee on Sunday and Monday, when DeSantis appeared visibly tired but spoke authoritatively about preparations overseeing Tropical Storm Idalia, which is forecast to become a major hurricane. He canceled campaign appearances and fundraisers, and told Floridians Sunday they could “rest assured” because “I am here” and would “get the job done.”DeSantis says politics won't interfere with storm response“He needs to be in Florida for as long as it takes,” said Adam Hollingsworth, the former chief of staff to Sen. Rick Scott (R-Fla.), who served as governor before DeSantis. “His presidential ambitions could be a distraction, but first Gov. DeSantis has to dance with the one who brought him. Right now, that's the people of Florida.”Though the shooting and looming storm are taking DeSantis away from campaigning for president following a high-profile debate, they'll also allow voters and donors to see the governor at work leading the hurricane response, letting the public assess how he balances multiple priorities, displays empathy and projects leadership in moments of tragedy. At the same time, the shooting has shined a spotlight on DeSantis' record and vulnerabilities on race, one of the areas for which he has faced the most criticism and controversy as governor.In times of tragedy, opponents are “looking for a misstep,” acknowledged Craig Fugate, who led Florida's emergency division under Gov. Jeb Bush and oversaw FEMA during the Obama administration.“They're looking for something to go wrong — particularly for the opponents; they're looking for something to capitalize on,” Fugate said.DeSantis began his Monday morning hurricane preparedness press conference by first addressing the mass shooting. He pledged $1 million in security funding to Edward Waters University, a historically Black university that the gunman is believed to have initially targeted, as well as $100,000 toward a charity for the families of the victims. He also deployed state law enforcement officials to evaluate the campus' security and make additional recommendations, pledging to continue to assist in the “days and weeks ahead.”But many Democrats in the state panned his response. They pointed to laws he enacted in Florida to carve up representation in a Black-majority district that eventually led a Black Democratic congressman, Rep. Al Lawson, to lose his seat. They also pointed to his policies, approved by the GOP-led Legislature, banning what he calls “critical race theory” in schools, as well as his defense of a public school curriculum on Black history that required middle-school teachers to instruct that enslaved people “developed skills which, in some instances, could be applied for their personal benefit.”Florida Minority House Leader Fentrice Driskell, a Black Democrat of Tampa, said it was “absolutely” the right decision for DeSantis to attend the vigil but added that she didn't want to give him a pass.“The reality is, a number of wrongheaded decisions about the state of Florida, and who we are as a people, I think contributed to this charged political climate that resulted in the violence that we saw,” Driskell said in an interview.The accused gunman, identified as Ryan Palmeter, had a racist manifesto and drew swastikas on his weapons. He also had a history of mental illness, having been involuntarily institutionalized for emergency mental health services as a teenager, police said.During DeSantis' vigil remarks Sunday, Democratic state Rep. Angela Nixon, who represents the district where the shooting took place, could be seen glaring at the governor in videos and photos widely shared on social media.“We feel the same,” the NAACP wrote on X, the social media platform formerly known as Twitter.AXIOS: Biden set to name first 10 drugs subject to Medicare negotiations.The blood-thinners Eliquis and Xarelto are among the 10 prescription medicines the Biden administration will seek lower Medicare prices for as part of a new program allowing the government to negotiate drug prices for America's seniors.Why it matters: The administration's landmark announcement Tuesday detailed the first-ever set of drugs subject to Medicare price negotiations, a longtime Democratic priority included in last year's Inflation Reduction Act over drug companies' fervent objections.Other drugs up for negotiation include:Jardiance, a diabetes drug.Januvia, also for diabetes.Farxiga, another diabetes drug.Entresto, for heart failure.Enbrel, for arthritis and psoriasis.Imbruvica, a blood cancer drug.Stelara, used on psoriasis, Crohn's disease and other illnesses.Fiasp, also used for diabetes.Of note: Insulin is already subject to a $35 monthly co-pay cap for Medicare prescription drug plan enrollees under a different provision of the IRA.State of play: The drugs' manufacturers will have just over a month to decide whether to participate in negotiations — which the industry is battling in court — or sit out the process, at the risk of significant financial penalty.Drugmakers who refuse to negotiate with Medicare face an excise tax of up to 95% of their U.S. sales, or they can withdraw their drugs from Medicare and Medicaid coverage, shutting them out of huge markets.What they're saying: "The cancer moonshot will not succeed if this administration continues to dismantle the innovation rocket we need to get there," Stephen Ubl, CEO of industry trade group PhRMA, said in a statement following the release of the list.Zoom out: The medicines up for negotiation were chosen from a list of the 50 products with the highest spending in Medicare's prescription drug program, Part D.The selected drugs accounted for 20% of Part D prescription costs between June 1, 2022 and May 31, 2023, according to the Health and Human Services Department.Some of the highest-cost Medicare drugs were not eligible for this round of negotiations, either because they still have market exclusivity, they're the only option for a rare disease or another factor.The prices won't take effect before the 2024 elections, but Democrats are expected to tout the negotiations, along with other drug cost reforms in the IRA, as part of their campaign messaging.What's next: The Centers for Medicare and Medicaid Services will submit price offers to the drug companies by Feb. 1, with negotiations continuing until next August.CMS will publish the drugs' final maximum fair prices by Sept. 1, 2024, and prices will go into effect in 2026.What we're watching: Ongoing legal challenges could draw out or halt the negotiation process.Drugmakers and allied groups have already filed eight lawsuits against the Medicare drug negotiation process, and more lawsuits could follow Tuesday's announcement.President Biden and his health officials committed this morning to fighting industry lawsuits."Let me be clear: I am not backing down. There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said in a statement.Nikki HaleyDAILY BEAST: Is it time for Republicans to take Nikki Haley seriously?According to a new Emerson College Polling survey, “Haley saw the largest increase in support among Republican candidates, jumping 5 points from 2 percent to 7 percent” following last week's debate.“Nikki Haley's support increased from about 2 percent to 9 percent among voters over 50 [years of age],” said Spencer Kimball, executive director of Emerson College Polling, “while Trump's support dropped within this age group from about 56 percent to 49 percent after the debate.”Republican Debaters Agreed on One Thing: They Hate Vivek RamaswamyThis jump is modest, inasmuch as it still leaves Haley in the single digits. But it's also no outlier. According to a poll conducted by The Washington Post, FiveThirtyEight, and Ipsos released last Thursday, voters were persuaded to at least give her a second look. “Pre-debate, 29 percent of GOP primary voters who watched the debate said they were considering voting for her,” according to the survey, “and that increased to 46 percent after the debate.”So how did she do it? Haley caught our attention by being first to hit Trump (from the right), when she criticized him for “adding eight trillion to our debt.” This surprised everyone, demonstrated courage, and put to rest the notion that she is merely running to be Trump's vice president.Haley also staked out a strong position on abortion. While stressing her pro-life beliefs, she made the pragmatic case that a federal abortion ban would require 60 votes. Instead, Haley urged Republicans to focus on consensus issues, like banning late-term abortions, making sure contraception is widely available, and supporting adoption as an alternative.Trump's former veep, Mike Pence, who supports a 15-week federal ban on abortion, took umbrage with this. “Nikki, you're my friend, but consensus is the opposite of leadership,” Pence scolded. (As the Never Trump conservative writer Jonah Goldberg has pointed out on his podcast, building consensus is often a key attribute of leadership.)The Republican Debate Was a Futile Pudding Wrestling MatchThis exchange, like others during that same debate, made it clear that in a general election Nikki Haley would likely be Joe Biden's most challenging opponent.Having served as governor of South Carolina and ambassador to the United Nations, she has the experience needed for the office. She also has sharp elbows. (“You have no foreign policy experience and it shows,” she told Vivek Ramaswamy.)At 51, Haley would present a stark contrast in terms of generational change, assuming that Joe Biden was still the Democratic nominee. And (unlike others) she is not staking out an abortion position that might render her effectively unelectable, should she become the Republican nominee.Haley (who frequently cites Margaret Thatcher's line, “If you want something said, ask a man. If you want something done, ask a woman”) was the only woman on that stage. Her identity, temperament, and policy positions could help chip away at the gender gap that has only grown in recent years.The obvious caveat here is that all of these things would make Haley a great candidate to beat Joe Biden if she somehow wins the Republican nomination. But that's an awfully big “if.”Kareem Abdul-Jabbar: GOP Debate Showed How Not to Pick a PresidentHaley's answer to this is to make the electability argument: “We have to face the fact that Trump is the most disliked politician in America,” she—and she, alone—averred during last week's debate.But will that dog hunt?Right now, the electability argument isn't persuading Republicans to jump off the Trump bandwagon, even though that argument is likely the only one that could ever work. At some point (perhaps after Donald Trump goes on trial and it's too late), Republicans might be convinced that, as entertaining as Trump is, he simply can't win.Based on all of this, you might expect me to suggest that it's time to clear the field—to rally every freedom conservative, Reagan Republican, and Never Trump conservative to coalesce around Haley as the GOP's last, best hope.Some of my colleagues are already there. The New York Times columnist David Brooks, for example, declared last week that “Wednesday's debate persuaded me that the best Trump alternative is not [Tim] Scott, it's Nikki Haley.”But here's my problem. Haley has been all over the map for years now. One day she's courageous and impressive, and the next day she's a pathetic Trump toady.Haley is a political chameleon, which makes me reluctant to ever trust her again.Trump and Ramaswamy Show Us How the Worst Get to the TopOn the other hand, anyone looking for purity (as it pertains to Trump) can also dismiss Pence and Chris Christie—both of whom supported Trump until Jan. 6—and a vast swath of today's leading Never Trumpers. As the Good Book says, “Who then can be saved?”Nikki Haley's got a long way to go before she clears the not-Trump lane of candidates, much less taking on the final boss himself. And though nothing has yet made a dent in Trump's domination of the GOP voter base, he's never run as a candidate on trial before. But the whole 91-felony indictment thing might just do the trick.If Haley can prove herself by stringing together two or three of these kinds of courageous performances—in which she not only characterizes Trump as the guy who already lost to Biden, but also that she's as real a conservative as any of the other contenders—there is a path to success.It's hardly guaranteed, and as I've noted, courage comes and goes with Haley. But in the “Matt Lewis primary,” you can count me among the 46 percent who are now considering voting for her.Read more at The Daily Beast.SEMAFOR: Nikki Haley's abortion message could catch on in the GOPMorgan Chalfant and Kadia GobaRepublicans worried about Democrats leveraging abortion (again) to make gains in 2024 want GOP candidates to take a page out of Nikki Haley's debate prep playbook.Haley dismissed the idea that a 15-week national abortion ban could pass through Congress. Instead, she argued the focus should be on finding “consensus” around banning “late-term abortions,” sustaining access to contraception, allowing doctors who don't support abortion refuse to perform them, and preventing women who get abortions from being penalized.Defeated Michigan gubernatorial candidate Tudor Dixon bluntly said on Fox News that Republicans would lose the messaging war in 2024 unless they followed Haley's “perfect response” in the debate.“No one really understood how important abortion would be in 2022 because no one had run in a post-Roe world, so we suddenly got attacked, viciously attacked, by the Democrats, and it is a winning message for them,” she said. Gov. Gretchen Whitmer highlighted Dixon's opposition to rape exceptions in abortion bans in their contest, which took place alongide a ballot initiative guaranteeing abortion rights that passed by a wide margin.“The only candidate on the stage that talked about how we should protect women and not demonize them was Nikki Haley,” Rep. Nancy Mace, R-S.C. said Sunday on CBS of the first GOP presidential debate. “And that is a message that we have to carry through. We have to be pro-woman and pro-life. You cannot go after women and attack them because they make a choice that you don't like or don't agree with.”And Rep. George Santos, R-N.Y., who represents a district President Biden won in 2020, told Semafor at a watch party last week: “She had probably the best-packaged message on abortion that I've heard, I want to say, in my entire adult life.”Haley might have won herself some fans, but her position wasn't a favorite within the anti-abortion movement, which has rallied around a 15-week federal ban as a minimum ask for candidates.

Florida Gov and GOP 2024 also-ran Ron DeSantis looks to lead in wake of violence and major hurricane | Former SC Gov and UN Ambassador under President Trump, Nikki Haley is having a moment, kind of | President Biden names first 10 drugs subject to negotations with Medicare | 60th anniversary of the March on WashingtonSong playsIntro by hostWelcome to Heartland Pod Wednesday!Support this show and all the work in the Heartland POD universe by going to heartlandpod.com and clicking the link for Patreon, or go to Patreon.com/HeartlandPod to sign up. Membership starts at $1/month, with even more extra shows and special access at the higher levels. No matter the level you choose, your membership helps us create these independent shows as we work together to change the conversation.Alright! Let's get into it: Hurricane in Florida / Shooting in FloridaPOLITICO: DeSantis knows how to handle a hurricane. The racist shooting poses a bigger dilemma.A racially-motivated Jacksonville tragedy, couple with a looming storm, pose big tests for the governor.Florida Gov. Ron DeSantis, center and his wife Casey, right, bow their heads during a prayer.Florida Gov. Ron DeSantis (center) and his wife Casey bow their heads during a prayer at a vigil for the victims of Saturday's mass shooting on Sunday, Aug. 27, 2023, in Jacksonville. | John Raoux/AP PhotoBy KIMBERLY LEONARD08/28/2023 04:14 PM EDTUpdated: 08/28/2023 05:12 PM EDTMIAMI — Florida Gov. Ron DeSantis' handling of back-to-back crises — a racist mass shooting and a potentially catastrophic hurricane — could help burnish his image as a can-do, effective governor or further damage his standing with Black Americans who have grown livid over his policies.Already, DeSantis' attempts to show leadership in the immediate aftermath of the Saturday shooting were poorly received by some Black lawmakers, Democrats and residents in Florida. In the hours after a 21-year-old white man killed three Black Floridians near a historically Black college in Jacksonville, several state Democrats blamed DeSantis, who is running for president, for creating an environment, through policies such as loosening gun laws and ending diversity programs, that helped hate fester.DeSantis has condemned the shooting and said “targeting people due to their race has no place in this state of Florida.” But attending a Sunday night vigil in Jacksonville, he was jeered and booed by people who had come out to remember the victims. At one point, a Jacksonville Democratic councilmember stepped in to calm the crowd, urging people to “put parties aside.” Later during the event, a pastor took issue with DeSantis describing the gunman as a “scumbag,” and said he should have used the word “racist” instead.The vigil stood in contrast to press conferences in Tallahassee on Sunday and Monday, when DeSantis appeared visibly tired but spoke authoritatively about preparations overseeing Tropical Storm Idalia, which is forecast to become a major hurricane. He canceled campaign appearances and fundraisers, and told Floridians Sunday they could “rest assured” because “I am here” and would “get the job done.”DeSantis says politics won't interfere with storm response“He needs to be in Florida for as long as it takes,” said Adam Hollingsworth, the former chief of staff to Sen. Rick Scott (R-Fla.), who served as governor before DeSantis. “His presidential ambitions could be a distraction, but first Gov. DeSantis has to dance with the one who brought him. Right now, that's the people of Florida.”Though the shooting and looming storm are taking DeSantis away from campaigning for president following a high-profile debate, they'll also allow voters and donors to see the governor at work leading the hurricane response, letting the public assess how he balances multiple priorities, displays empathy and projects leadership in moments of tragedy. At the same time, the shooting has shined a spotlight on DeSantis' record and vulnerabilities on race, one of the areas for which he has faced the most criticism and controversy as governor.In times of tragedy, opponents are “looking for a misstep,” acknowledged Craig Fugate, who led Florida's emergency division under Gov. Jeb Bush and oversaw FEMA during the Obama administration.“They're looking for something to go wrong — particularly for the opponents; they're looking for something to capitalize on,” Fugate said.DeSantis began his Monday morning hurricane preparedness press conference by first addressing the mass shooting. He pledged $1 million in security funding to Edward Waters University, a historically Black university that the gunman is believed to have initially targeted, as well as $100,000 toward a charity for the families of the victims. He also deployed state law enforcement officials to evaluate the campus' security and make additional recommendations, pledging to continue to assist in the “days and weeks ahead.”But many Democrats in the state panned his response. They pointed to laws he enacted in Florida to carve up representation in a Black-majority district that eventually led a Black Democratic congressman, Rep. Al Lawson, to lose his seat. They also pointed to his policies, approved by the GOP-led Legislature, banning what he calls “critical race theory” in schools, as well as his defense of a public school curriculum on Black history that required middle-school teachers to instruct that enslaved people “developed skills which, in some instances, could be applied for their personal benefit.”Florida Minority House Leader Fentrice Driskell, a Black Democrat of Tampa, said it was “absolutely” the right decision for DeSantis to attend the vigil but added that she didn't want to give him a pass.“The reality is, a number of wrongheaded decisions about the state of Florida, and who we are as a people, I think contributed to this charged political climate that resulted in the violence that we saw,” Driskell said in an interview.The accused gunman, identified as Ryan Palmeter, had a racist manifesto and drew swastikas on his weapons. He also had a history of mental illness, having been involuntarily institutionalized for emergency mental health services as a teenager, police said.During DeSantis' vigil remarks Sunday, Democratic state Rep. Angela Nixon, who represents the district where the shooting took place, could be seen glaring at the governor in videos and photos widely shared on social media.“We feel the same,” the NAACP wrote on X, the social media platform formerly known as Twitter.AXIOS: Biden set to name first 10 drugs subject to Medicare negotiations.The blood-thinners Eliquis and Xarelto are among the 10 prescription medicines the Biden administration will seek lower Medicare prices for as part of a new program allowing the government to negotiate drug prices for America's seniors.Why it matters: The administration's landmark announcement Tuesday detailed the first-ever set of drugs subject to Medicare price negotiations, a longtime Democratic priority included in last year's Inflation Reduction Act over drug companies' fervent objections.Other drugs up for negotiation include:Jardiance, a diabetes drug.Januvia, also for diabetes.Farxiga, another diabetes drug.Entresto, for heart failure.Enbrel, for arthritis and psoriasis.Imbruvica, a blood cancer drug.Stelara, used on psoriasis, Crohn's disease and other illnesses.Fiasp, also used for diabetes.Of note: Insulin is already subject to a $35 monthly co-pay cap for Medicare prescription drug plan enrollees under a different provision of the IRA.State of play: The drugs' manufacturers will have just over a month to decide whether to participate in negotiations — which the industry is battling in court — or sit out the process, at the risk of significant financial penalty.Drugmakers who refuse to negotiate with Medicare face an excise tax of up to 95% of their U.S. sales, or they can withdraw their drugs from Medicare and Medicaid coverage, shutting them out of huge markets.What they're saying: "The cancer moonshot will not succeed if this administration continues to dismantle the innovation rocket we need to get there," Stephen Ubl, CEO of industry trade group PhRMA, said in a statement following the release of the list.Zoom out: The medicines up for negotiation were chosen from a list of the 50 products with the highest spending in Medicare's prescription drug program, Part D.The selected drugs accounted for 20% of Part D prescription costs between June 1, 2022 and May 31, 2023, according to the Health and Human Services Department.Some of the highest-cost Medicare drugs were not eligible for this round of negotiations, either because they still have market exclusivity, they're the only option for a rare disease or another factor.The prices won't take effect before the 2024 elections, but Democrats are expected to tout the negotiations, along with other drug cost reforms in the IRA, as part of their campaign messaging.What's next: The Centers for Medicare and Medicaid Services will submit price offers to the drug companies by Feb. 1, with negotiations continuing until next August.CMS will publish the drugs' final maximum fair prices by Sept. 1, 2024, and prices will go into effect in 2026.What we're watching: Ongoing legal challenges could draw out or halt the negotiation process.Drugmakers and allied groups have already filed eight lawsuits against the Medicare drug negotiation process, and more lawsuits could follow Tuesday's announcement.President Biden and his health officials committed this morning to fighting industry lawsuits."Let me be clear: I am not backing down. There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said in a statement.Nikki HaleyDAILY BEAST: Is it time for Republicans to take Nikki Haley seriously?According to a new Emerson College Polling survey, “Haley saw the largest increase in support among Republican candidates, jumping 5 points from 2 percent to 7 percent” following last week's debate.“Nikki Haley's support increased from about 2 percent to 9 percent among voters over 50 [years of age],” said Spencer Kimball, executive director of Emerson College Polling, “while Trump's support dropped within this age group from about 56 percent to 49 percent after the debate.”Republican Debaters Agreed on One Thing: They Hate Vivek RamaswamyThis jump is modest, inasmuch as it still leaves Haley in the single digits. But it's also no outlier. According to a poll conducted by The Washington Post, FiveThirtyEight, and Ipsos released last Thursday, voters were persuaded to at least give her a second look. “Pre-debate, 29 percent of GOP primary voters who watched the debate said they were considering voting for her,” according to the survey, “and that increased to 46 percent after the debate.”So how did she do it? Haley caught our attention by being first to hit Trump (from the right), when she criticized him for “adding eight trillion to our debt.” This surprised everyone, demonstrated courage, and put to rest the notion that she is merely running to be Trump's vice president.Haley also staked out a strong position on abortion. While stressing her pro-life beliefs, she made the pragmatic case that a federal abortion ban would require 60 votes. Instead, Haley urged Republicans to focus on consensus issues, like banning late-term abortions, making sure contraception is widely available, and supporting adoption as an alternative.Trump's former veep, Mike Pence, who supports a 15-week federal ban on abortion, took umbrage with this. “Nikki, you're my friend, but consensus is the opposite of leadership,” Pence scolded. (As the Never Trump conservative writer Jonah Goldberg has pointed out on his podcast, building consensus is often a key attribute of leadership.)The Republican Debate Was a Futile Pudding Wrestling MatchThis exchange, like others during that same debate, made it clear that in a general election Nikki Haley would likely be Joe Biden's most challenging opponent.Having served as governor of South Carolina and ambassador to the United Nations, she has the experience needed for the office. She also has sharp elbows. (“You have no foreign policy experience and it shows,” she told Vivek Ramaswamy.)At 51, Haley would present a stark contrast in terms of generational change, assuming that Joe Biden was still the Democratic nominee. And (unlike others) she is not staking out an abortion position that might render her effectively unelectable, should she become the Republican nominee.Haley (who frequently cites Margaret Thatcher's line, “If you want something said, ask a man. If you want something done, ask a woman”) was the only woman on that stage. Her identity, temperament, and policy positions could help chip away at the gender gap that has only grown in recent years.The obvious caveat here is that all of these things would make Haley a great candidate to beat Joe Biden if she somehow wins the Republican nomination. But that's an awfully big “if.”Kareem Abdul-Jabbar: GOP Debate Showed How Not to Pick a PresidentHaley's answer to this is to make the electability argument: “We have to face the fact that Trump is the most disliked politician in America,” she—and she, alone—averred during last week's debate.But will that dog hunt?Right now, the electability argument isn't persuading Republicans to jump off the Trump bandwagon, even though that argument is likely the only one that could ever work. At some point (perhaps after Donald Trump goes on trial and it's too late), Republicans might be convinced that, as entertaining as Trump is, he simply can't win.Based on all of this, you might expect me to suggest that it's time to clear the field—to rally every freedom conservative, Reagan Republican, and Never Trump conservative to coalesce around Haley as the GOP's last, best hope.Some of my colleagues are already there. The New York Times columnist David Brooks, for example, declared last week that “Wednesday's debate persuaded me that the best Trump alternative is not [Tim] Scott, it's Nikki Haley.”But here's my problem. Haley has been all over the map for years now. One day she's courageous and impressive, and the next day she's a pathetic Trump toady.Haley is a political chameleon, which makes me reluctant to ever trust her again.Trump and Ramaswamy Show Us How the Worst Get to the TopOn the other hand, anyone looking for purity (as it pertains to Trump) can also dismiss Pence and Chris Christie—both of whom supported Trump until Jan. 6—and a vast swath of today's leading Never Trumpers. As the Good Book says, “Who then can be saved?”Nikki Haley's got a long way to go before she clears the not-Trump lane of candidates, much less taking on the final boss himself. And though nothing has yet made a dent in Trump's domination of the GOP voter base, he's never run as a candidate on trial before. But the whole 91-felony indictment thing might just do the trick.If Haley can prove herself by stringing together two or three of these kinds of courageous performances—in which she not only characterizes Trump as the guy who already lost to Biden, but also that she's as real a conservative as any of the other contenders—there is a path to success.It's hardly guaranteed, and as I've noted, courage comes and goes with Haley. But in the “Matt Lewis primary,” you can count me among the 46 percent who are now considering voting for her.Read more at The Daily Beast.SEMAFOR: Nikki Haley's abortion message could catch on in the GOPMorgan Chalfant and Kadia GobaRepublicans worried about Democrats leveraging abortion (again) to make gains in 2024 want GOP candidates to take a page out of Nikki Haley's debate prep playbook.Haley dismissed the idea that a 15-week national abortion ban could pass through Congress. Instead, she argued the focus should be on finding “consensus” around banning “late-term abortions,” sustaining access to contraception, allowing doctors who don't support abortion refuse to perform them, and preventing women who get abortions from being penalized.Defeated Michigan gubernatorial candidate Tudor Dixon bluntly said on Fox News that Republicans would lose the messaging war in 2024 unless they followed Haley's “perfect response” in the debate.“No one really understood how important abortion would be in 2022 because no one had run in a post-Roe world, so we suddenly got attacked, viciously attacked, by the Democrats, and it is a winning message for them,” she said. Gov. Gretchen Whitmer highlighted Dixon's opposition to rape exceptions in abortion bans in their contest, which took place alongide a ballot initiative guaranteeing abortion rights that passed by a wide margin.“The only candidate on the stage that talked about how we should protect women and not demonize them was Nikki Haley,” Rep. Nancy Mace, R-S.C. said Sunday on CBS of the first GOP presidential debate. “And that is a message that we have to carry through. We have to be pro-woman and pro-life. You cannot go after women and attack them because they make a choice that you don't like or don't agree with.”And Rep. George Santos, R-N.Y., who represents a district President Biden won in 2020, told Semafor at a watch party last week: “She had probably the best-packaged message on abortion that I've heard, I want to say, in my entire adult life.”Haley might have won herself some fans, but her position wasn't a favorite within the anti-abortion movement, which has rallied around a 15-week federal ban as a minimum ask for candidates.

Our transcription service is still very BETA. Get full access to INDIGNITY at indignity.substack.com/subscribe

Sometimes biologic drugs like Enbrel and Humira have little effect on patients. One of the reasons this might occur is when the patient has low vagus nerve activity. In this video Clint explains what this means and how you can correct it easily at home to improve your health and potentially the effectiveness of your biologic treatment. For the transcription and for more helpful information visit http://www.rheumatoidsolutions.com Paddison Program for Rheumatoid Arthritis http://www.paddisonprogram.com/rheumatoid-arthritis Rheumatoid Support - http://www.rheumatoidsupport.com

Christopher Posner Chief Executive Officer, President, and Director Mr. Posner has served as our President and Chief Executive Officer since November 2021 and has served as a member of our Board since August 2018. He has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. From July 2017 to October 2021, he served as the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University. Please see korsuva.com/pi for Full Prescribing Information.

Ali and Cheryl discuss how overwhelming medication changes can be, and Ali describes what it was like to switch doses of methotrexate, switch to a new biologic medication and add prednisone and NDSAIDs in the mix. Ali & Cheryl also discuss what it's like to have costochondritis and how they cope with unresolved health issues while still trying to live a full, joyful life. This episode also includes reflections about how to cope with social media jealousy within the chronic illness community, how to set boundaries with friends and loved ones during Covid times, and more.  This interview was conducted in February 2022.Episode at a glance:Flare up leads to medication changes: Ali shares what it was like to switch biologics, take a course of prednisone and add in NSAID (Non steroidal anti inflammatory medications) and alter her methotrexate dosageHeartbreak: when Ali discovered she wasn't in medicated remission, she feels heartbrokenEmergency Room Visit: Ali goes to the emergency room with severe pelvic pain, doesn't get any clear answers, follows up with both Gynecology and GI doctorsCostochondritis and “hypochondriac” accusations: Cheryl & Ali discuss their experiences with costochondritis and how they were both accused of being hypochondriacs before their accurate diagnosis of costochondritisCoping: we discuss how we cope with the ups and downs of chronic illness lifeCovid and social life: discussion about how to set boundaries socially around covid precautionsSocial Media and Jealousy: reflections about how to cope when others seem to be doing better than youEveryone is different: there's no badge for managing RA a certain wayAli's advice to people just starting out on Methotrexate, or who are hesitant about itMedical disclaimer:All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, a community support & education program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. Join the waitlist for the next group, which starts in October 2022!Rheumatoid Arthritis Roadmap,  a self-paced online course Cheryl created that teaches you how to confidently manage your physical, social and emotional life with rheumatoid arthritis.Episode SponsorsFor full episode details including a transcript, please go to the Arthritis Life Website at www.MyArthritisLife.Net

Anuj Bhardwaj is the CEO of SecondWave Systems which is a wearable ultrasound noninvasive therapy especially for suppressing chronic inflammation and pain signals. ***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services here*** Top 3 Takeaways:  "We're going to use a disposable coupling component that a patient uses to adhere this and couple it to the body for 18 minutes while they remain in a reasonably sedentary condition. They would do that once a day." "The cost of the healthcare system is often between one to $200,000 per year for patients that take biologics like Enbrel. So that's a huge burden on the system" "My advice to other companies like us would be to look at the SBIR program. We're very strong advocates of it. It's really been the main engine that launched us. I'd advise looking at NIH, BARDA, and others too. Then consider if they fit within the mission of what a company is doing and apply." 0:30 "Do you want to describe yourself and your technology?" 2:30 "Let's talk about the technology, who's it for?" 9:15 Iris Biomedical ad sponsorship 10:15 "You're not using electricity, but you're using ultrasound, which is something that's a little bit more rarely used. Why are you using this and how does it work?" 12:15 "What kind of treatments would you guys be able to provide?" 15:30 "So what fraction of the $100,000-$200,000 / year Rheumatoid Arthritis costs would you guys represent?" 16:30 Do you want to talk about the FDA approval process for a wearable? 18:15 Do you want to talk about your sources of funding so far? 22:30 "What is one of the biggest challenges in this work?" 25:00 "Are you looking for people to join or are you looking for anything in particular?"

One quick way to start arguing with a politician is to mention prescription drug pricing changes. This issue affects everyone, so I'm going to give you the brief story for how drugs get from the manufacturer to your front door as well as go over the underlying reasons for why they cost a ton.We're probably better at tracking drug pricing than remembering to get rid of the trash. For example, if you're taking blood pressure meds that cost $2 per pill per day now and next year each pill costs $2.10 daily, you might have the difficult choice to prioritize savings versus your health. This potential dilemma is why the Centers for Medicare and Medicaid Services, or CMS, keeps a watch on various drugs they pay for and whether price levels are higher or lower than inflation. Economists, politicians, and other insurance plans often reference these data. The most recent analysis by CMS on this was taken from data spanning 2019 to 2020, right before inflation became severe—CMS's review back then referenced inflation as 1%. Thankfully, whoever reviewed the data again in February 2022 put both the Part B and Part D drug repricing in context. For those of us who are not yet on Medicare, Part B just refers to medications that are mainly administered in hospitals or medical offices (such as cancer therapies or infusion treatments), while Part D addresses most of the drugs you'd take at home, like diabetes or acne meds. Prices on 50% of the part D covered drugs and 48% of part B drugs rose more than 1% in the study's period. If we filter down the data to compare the changes against our 2021-2022 inflation, prices for 17% of part D and 18% of part B drugs during the study period rose above 7.5%. Although what I'm going to say next might be hard to believe, drug prices can decrease. Such a phenomenon tends to happen when a pharmaceutical company has an expiring drug patent or if there is serious competition from a product like a biosimilar. For reference, CMS found that 41% of part D and 46% of part B medications had nominal price reductions. That being said, the real magnitude of high-impact drug price changes varies if the pharmaceutical company raises the cost per dose or the cost of the overall medication's flat lifetime, which, as you may imagine, depends on treatment method. In general, the beginning and midway points of the year are when drug companies make significant pricing decisions. The list price of a therapy stated by any pharma company is a proxy for how much less or more you're paying later after discounts. Part of the issue is that drugs are still relatively expensive in the US versus our neighbors like Canada and Mexico, even after insurance coverage takes a lot off the top.Before going into the food chain of drugs, we should know how drugs pop into existence. Because of government orgs like the FDA, pharma companies do time-intensive research to find a potential drug candidate, review its best medium, put it through phase one/two/three trials, and get it reviewed by regulators before market approval. The US government in particular is reasonably strict with drug development and very lax with pricing and marketing controls. I'd argue that lack of both marketing regulation and post-approval drug efficacy review are what set the bar high for prices to begin with. When it comes to a drug for rheumatoid arthritis like Humira, which in 2021 had the most revenue among all drugs not including the Covid vaccines, it's easy to find efficacy data from the company's primary studies but not as simple to find rigorous peer-reviewed long-term head-to-head comparisons between Humira and something like Enbrel which is also used for similar conditions. Most pharma groups like to say that high research and development costs are why prices need to be steep. In March 2020, the Journal of the American Medical Association reviewed medication discovery R&D expenses taken from 2009 to 2018 and found the median cost of a new drug, start to finish, is just under $1B. Years and years of work could still lead to a drug's complete failure. Highly organized trial and error is how the business works. Other factors besides the development itself that raise or lower prices include competition, efficacy and safety. Patents also extend the lifetime of this pseudo-monopolistic pricing, which is why generic drugs for a given condition are less costly than brand-name choices. However, the Covid vaccines or monoclonal antibodies are recent and helpful reminders that we need consistent medical therapy innovation. Hence, pricing is something government and industry should mitigate rather than punish. I'm fully aware that's easy to say and hard to execute, but all the info we covered so far begins to inform us on how drugs move from the factory to our local pharmacy.The first stop in a brand-new pill's journey leaving its manufacturing plant is a wholesaler. These are the first bulk purchasers for the medication where the “average selling price” comes into play. Then pharmacies and hospitals buy from those wholesalers for what is called the “actual acquisition cost” to dispense the drug for patients later at the “cash price” before coverage and benefits. I'll post a helpful info-graphic from the site US Pharmacist that shows this supply dynamic on my Substack page found at rushinagalla.substack.com. Because the wholesalers are businesses as well, they will sell the bulk drugs at some premium. Of course, when it comes to US healthcare economics, there's a curveball here. That curveball would be the fact that you, the patient, are not the true end purchaser. This is because most insurance plans use pharmacy benefit managers (PBMs) to negotiate in secret the lowest possible prices. Medicaid and pharmacy benefit managers in a few states do impose price ceilings for certain drugs, but a drug's price on any given day varies based on who's paying. The best way to see this logic is by pretending that you mow lawns in a neighborhood. You're going to charge a different rate for the lawn owners in front of a mansion versus the lawn owners in front of a shack. Pharmaceutical companies also give rebates to benefit managers to win a better placement on an insurance plan's formulary, regardless of true efficacy. Going any further demands another episode by itself, but the main takeaway I'd like you to have is that drugs get priced as they are currently because they pass though many hands before getting to you and the facts of true effectiveness get shrouded in mystery. Collaboration, rather than division, between government and the private sector as well as innovation with medication data transparency are the next areas to reach common ground on drug prices.With that done, let's get away from the bird's eye view and think about the day-to-day for a moment. After going to the clinic, your doctor whips up the perfect treatment in mind for your medical issue and there's a particular drug you need to string everything together. At this moment, a strange and way-too-official-sounding obstacle called the prior authorization prevents you from getting past the starting line. Going over why prior authorizations happen and how to deal with them is next week's theme. Stayed tuned and subscribe to Friendly Neighborhood Patient for more commentary on the medical world. I'll catch you at the next episode. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit rushinagalla.substack.com

Five years ago, when Dr. Leslie Alexandre arrived in Seattle to lead the industry group Life Science Washington, she found a community in a mild state of shock. "One of the real challenges was our ecosystem had tons of great research going on, and many wonderful companies, but I think our industry was a little bit in the doldrums in 2016, in part because Amgen had just completed moving out of Elliott Bay," she said. "It started in 2014. And when I arrived, it was just the last people." Amgen was the giant that five years earlier acquired Seattle's homegrown biotech standout Immunex, known for developing the Enbrel arthritis drug, still widely prescribed to this day. Immunex was based on a big waterfront campus, which today is home to Expedia Group's global headquarters. But there had been hopes in the local community that Amgen would maintain and even expand its operations in the region after the Immunex acquisition. "And having it move away was kind of, 'Oh my gosh, one more company, one more great company created here in Seattle, breathtaking research commercialization. And now it's gone," Alexandre said. But that's just the beginning of the story. On this episode of the GeekWire Health Tech Podcast, what happened next, and where the Seattle region's life sciences industry stands today. Our guest, Leslie Alexandre is the President and CEO at life science, Washington, an organization that aims to put Washington state at the forefront of global life science innovation, who recently announced her plans to retire at the end of the year. The organization is holding its annual Washington State Life Science Summit virtually this week, Thursday Oct. 21. Dr. Alexandre received her Doctorate of Public Health from UCLA and has held leadership roles at startups, Fortune 500 companies, research institutions and non-profit organizations. She ran the North Carolina Biotechnology Center from 2002-2007. Episode produced and edited by GeekWire co-founder Todd Bishop, with reporting and research by Charlotte Schubert, GeekWire health and life sciences reporter, who also joins us on this episode. See omnystudio.com/listener for privacy information.

Dr. Cindy Jacobs, PhD, MD, President and Chief Medical Officer at Achieve Life Sciences discusses the grant that was awarded from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for the cessation of nicotine e-cigarette use. #AchieveLifeSciences Cindy Jacobs, Ph.D., M.D. · President & Chief Medical Officer, Achieve Life Sciences Inc. Dr. Jacobs is an experienced executive in drug development with expertise in several indications and over 30 years' experience in Biotechnology/Pharmaceutical industry. Dr Jacobs has achieved regulatory success in several product approvals. Prior to joining Achieve Life Sciences in 2017, Dr. Jacobs served as OncoGenex's Executive Vice President and Chief Medical Officer since August 2008, and had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Bachelor's degree in Microbiology from Montana State University, her Master's degree and Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. She has in-depth biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, clinical operations, Phase 1-4 trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. Based on her preclinical work at Immunex Corporation, she is one of 2 inventors on the patent for Enbrel.

In the early '80s, Linda Sloate was a 30-year old mom raising three little kids when she became one of an estimated 20 million people worldwide living with rheumatoid arthritis (RA). It has been a 40-year struggle filled with dozens of treatments and surgeries. Today there is new hope for patients as researchers have come together for a collaborative project to uncover how RA begins – and how to stop it in its tracks.

More details found in the shownotes at www.yourfertilitypharmacist.com

Brady Mavetz is 24 years old, from the suburbs of Minnesota and raised in a supportive family. Became very competitive in his youth. He wasn’t sure of what career to go into, so he trained to be an Engineer only to discover that it wasn’t his passion. He pushed through the program because he thought it was what people wanted him to do. He was operating under the assumption that it took hard work that determined his value. He holds this mentality responsible for leading him into disease. Here are some key points within the interview. I asked him, why spread this message and this is what he said. Part of recovering from an “incurable disease”, when you're in it, the fear that you can never get out of the clutches of that reality can be quite scary. He mentions needing many testimonials in order to believe that it was actually possible. He wondered, how could the mind be possible for controlling physical pain?He discusses his choice to have Arthroscopic hip surgery performed, which led to a year of rehab and no improvement.  When he began taking Biologics he went from a 8 or 9 in pain down to 7 or 6. Switched to Enbrel which helped a little more but not much. Was working with Ralph Ruiz for a couple weeks and was getting fearful because he still felt pain. Ralph offered this advice “just imagine that this program doesn’t work for you, that you have already failed” and within a week Brady’s pain had gone down significantly. Brady realized he was putting too much pressure on himself.  Brady goes on to say, don’t resist emotion as it comes up. It has nothing to do with reality. The more he sat with these uncomfortable emotions, the easier it became. A lot of the pain comes up because of the resistance to feeling and allowing this emotion to be there.  He is learning to trust himself more rather than trying to produce himself through the eyes of other people Go to 41:50 to hear Brady describe how bizarre it is to feel pain disappear by essentially doing nothing but admitting to thoughts and emotions. His belief was that nothing is easy, so he was over complicating everything, over thinking and it turns out it was much easier than he could imagine and it didn’t really involve thinking. He learned what was required was to let the fear of not knowing what he was doing be there. To let it be there. Go to 46:40 where he sums it all up. What he says here is what can be learned from pain and discomfort.  49:00 How working with a coach can be helpful.  51:35 What someone may learn if they started training in mind body work. 55:25  Listen to this. 58:35 How he is doing now. Getting off all medication.1:11:20  If you are questioning the validity of the mind body connection.My email address eisner00@gmail.comRalph's Website. https://ralphitness.comCheck out his Michael Brown Interview.  He does a great discription of intergrating emotion. https://www.youtube.com/watch?v=O1EeOI33f2o&t=1289s 

Pfizer's History of Crimes and Misdemeanors   Richard Gale and Gary Null Progressive Radio Network, March 10, 2021     Whenever it is necessary to make an evaluation of the efficacy and safety of conventional drug-based medicine, it is imperative to include the rising rate of iatraogenic injuries and deaths – medical errors – that has become the third leading cause of death in the US after cardiovascular disease and cancer. The majority of these deaths are caused by FDA approved drugs' adverse effects and when patients are prescribed multiple medications in the absence of thorough clinical research to determine the safety of their synergistic effects.  Consequently our health agencies' oversight and monitoring of drugs on the market is dismal and deadly.    Among the top pharmaceutical companies whose drugs and products have most contributed to the nation’s iatrogenic epidemic is the $51 billion multinational behemoth Pfizer Inc, the world’s third most profitable drug maker. Pfizer is one of America’s oldest pharma firms, founded by Charles Pfizer and Charles Erhart in a Brooklyn red brick building in 1849. The chemical company began to boom in the 1880s after becoming the leading manufacturer of the chelating, flavoring and preservative agent citric acid. With its expertise in fermentation chemistry, Pfizer later became a leader in the production of penicillin and ascorbic acid (Vitamin C). Today its 300-plus drugs are commonplace in American doctors’ tool kits: Zoloft, Zantac, Viagra, Enbrel, Flagyl, Lipitor, and several antibiotics. It is also a major player in the generic drug market and is rapidly becoming a leading vaccine maker with its pneumococcus vaccine (Prevnar) and more recently with its controversial mRNA vaccine against the SARS-CoV2 virus. In the irrational panic to quickly get a vaccine against the SARS virus to market, its Covid-19 vaccine was the first to receive emergency use authorization   Pfizer's legacy of lawsuits goes back to the late 1950s. According to the Corporate Research Project, it “has been at the center of controversies over its drug pricing for more than 50 years.” Back in 1958 it was charged by the Federal Trade Commission for price fixing and making false statements to dubiously acquire a patent for tetracycline. Two years later the Justice Department filed criminal antitrust charges against Pfizer’s board chairman and president John McKeen on the matter. Again in 1996, the drug company paid out $408 million to settle another lawsuit for price fixing and gouging pharmacies. In 2002, Pfizer was caught defrauding the federal Medicaid program for over-charging its flagship cholesterol drug Lipitor. Other similar charges include a $784 million settlement for underpaid rebates to Medicaid and $107 million fine for overcharging its epilepsy drug phenytoin sodium.   The company has even stooped so low as to engage in bogus advertising. Shortly after the Second World War, Pfizer created snazzy ads for the Journal of the American Medical Association for its antibiotic line. The ads included named physicians endorsing its drugs. However, according to a Saturday Review investigation, the doctors turned out to be completely fictitious.   As the company is positioned to earn $19 billon from its Covid-19 vaccine, at the same time it is legally battling against hundreds of lawsuits due to its popular heartburn drug, Zantac, being contaminated with the carcinogen N-nitrosodimethylamine (NDMA), an “extremely hazardous” toxin used in rocket fuel and industrial lubricants. Although the FDA erroneously claims that Zantac’s NDMA levels are low, they have still been measured to be between 3,000 and 26,000 times higher than the FDA’s safety cut-off point. Another adverse effect of NDMA is hepatotoxicity leading to liver fibrosis and scarring.   According to the law firm Matthews and Associates, since “the history of Pfizer is rife with so much subterfuge and under-the-table dealing that the company will need all the help it can get to promote confidence in its hastily assembled Covid vaccine.” If the mainstream media were to honestly cover the NDMA trial underway and other Pfizer confrontations with the law, perhaps its vaccine would not be receiving such uncritical fanfare. There would be more scrutiny and warranted suspicion to question how Pfizer could have developed a truly safe and effective vaccine in such a short period of time.   In our earlier reviews of the criminal records of Merck and Johnson and Johnson, we did not find evidence of the depths of demented ethical behavior solely to manipulate its market control as we do with Pfizer. In fact, Pfizer seemingly is in competition to outdo notorious hedge fund vulture capitalist and underworld strategies to bully governments in return for securing supplies of its Covid-19 vaccine. For example, Pfizer demanded that Argentina pay the company compensation for any civil lawsuits filed against it. The government compromised and ruled that Pfizer would only pay fines for any negligence on the company’s behalf with respect to supply and distribution. But that was not agreeable to the vaccine maker. Instead it then demanded that Argentina provide its sovereign assets –bank reserves, military bases and embassy buildings – as collateral to secure vaccine supplies.    In Brazil, Pfizer’s aggressive and malignant efforts failed. It demanded that the Brazilian government turn over a guaranteed fund deposited in a foreign bank account and that the government would waive its sovereign assets abroad. Pfizer also demanded that it not be held legally liable for any injuries or deaths due to its vaccine. Correctly, President Bolsonaro called Pfizer’s demands “abuse” and rejected the deal.    If this gives the impression that Pfizer is a serial predator on poorer foreign nations, Argentina and Brazil are only the most recent examples. In 1996, the company conducted illegal experimental trials with an unapproved experimental antibiotic, Trovan, on Nigerian children without parental knowledge or consent. The case was not raised in a US federal court until 2001 after thirty Nigerian families sued. After 100 children were given the drug as guinea pigs, “eleven children in the trial died, others suffered brain damage, were partly paralyzed or became deaf.”  Nigerian medical experts ruled that Pfizer violated international law and the US federal case was eventually settled a decade later for an undisclosed amount.    Pfizer’s dirty politics and mafia-like activity in the Nigeria scandal, reminding us of Monsanto’s sleazy schemes, goes beyond the dangers of an experimental antibiotic. Wikileaks made available State Department cables showing that Pfizer had hired spies to dig up dirt to frame a former Nigerian attorney general in order to get the lawsuit dropped. It also tried to shift the blame of the scandal on Doctors Without Borders by making a false claim that the non-profit charitable group was responsible for dispensing the antibiotic.    Already in the US, thanks to Reagan’s Vaccine Injury Compensation Act, vaccine makers are off the hook for being held legally accountable for vaccine adverse effects. Now the company is demanding that other nations change their laws solely for Pfizer to secure maximum profits from its Covid vaccine. Pfizer’s actions are utterly parasitical. Nor should we forget that the development of its vaccine has largely been publicly funded. Its Covid vaccine partner Biontech received $445 million from the German government, and Pfizer has received almost $2 billion from US taxpayers as pre-payment for a vaccine.    Pfizer’s leech-like behavior goes back even further. In 2003, after it appeared that Congress might pass a bill to permit cheaper prescription drugs in Canada for sale in the US, Pfizer attempted to change the rules of the game and demand Canadian pharmacies to order directly from Pfizer rather than wholesalers in order to dominate the market and interrupt the supply chain.    Pfizer’s track record for fines and lawsuits for violation of its drug safety profiles and ethical marketing are equally damning. In 2009, it was fined $2.3 billion for what was then the largest healthcare felony settlement in US pharmaceutical history for illegally promoting its drugs, including its painkiller Bextra. $1.2 billion was just for the criminal fine; at the time, this was the largest ever imposed in the US for any issue. In 2011, it was found guilty of racketeering charges for illegally marketing its anticonvulsant drug Neurontin and paid $142 million. Three years later Pfizer was fined $430 million to settle criminal charges for bribing doctors to promote and prescribe the same drug.     Nor should we ignore Pfizer’s dreadful environmental record: 1971 - Long time illegal dumping of a million gallons of industrial waste annually from its Groton plant into the Long Island Sound;  1991 - A $3.1 million fine for refusing to install pollution control equipment in its Delaware River plant 1994 – A $1.5 million fine for illegal dumping at a toxic waste site in Rhode Island 2003 – Paid a $700 million settlement for dumping PCBs in Anniston, Alabama.   Now, we are facing the widespread distribution of Pfizer’s experimental mRNA Covid-19 vaccine wherein the trials to determine its level of safety and efficacy are still underway. It is still too early to make any determination of Pfizer having been engaged in any nefarious activities to get its vaccine rushed to the public. Impropriety and medical negligence so far lies on our government’s shoulders and our bought-off corporate media. Federal health agencies simply ignored their regulatory obligations and gave the vaccine a green light prematurely. Nevertheless, reports of injuries and deaths continue to mount and we will not have any sense of the full cost to human life and suffering from vaccine injuries for a while. In the meantime, China has suspended the mRNA vaccine after a flurry of deaths among Norwegian elderly. The Gibraltar Chronicle reported the deaths of 13 people within two days of receiving Pfizer’s vaccine and that number has risen to over 50 on the tiny island. Hundreds of vaccinated Israelis are still coming down with SARS-CoV2 infections after vaccination. The highly prestigious journal Science reported the growing concerns over the Pfizer vaccine’s polyethylene glycol nanoparticle and its relationship to the growing number of rare but serious allergic reactions and cases of anaphylaxis. And in a briefing document released by the CDC’s Vaccines and Related Biological Products Advisory Committee gave warning that the Pfizer vaccine trials give indication of unusual and unexpected antibody responses, cytokine storms and pathogenic priming that give rise to critical illness and death.    Therefore there is no evidence whatsoever that Pfizer’s Covid-19 vaccine can scientifically and consensually be ruled as safe. But as we have observed from Pfizer’s litany of criminal activities above, safety and effectiveness of a drug or product has never been a priority in the company’s executive office.    All told, these examples of Pfizer's culture of greed, deception, political maneuvering and mafia-like tactics has collectively injured countless people. Pfizer is a global corporation. Its drugs, and now its Covid-19 vaccine are marketed globally. To better understand Pfizer, the company should be perceived foremost as a cash cow for Wall Street. Its prime directive is selling drugs; its history of misdemeanors and crimes should indicate the company holds no integrity or medical ethics with a sincere commitment to prevent and treat disease. For firms such as Pfizer, injuries and deaths are the necessary collateral damage of getting poorly tested products on the market and as fast as possible. In our opinion, a black box warning should be slapped on the Pfizer logo. And should we trust such a company with the potential to vaccinate an enormous percent of the world population with an experimental vaccine?  

Send yours to askjeff@comeonover.com! He may just answer it in a future podcast! Andrea, Your Local Neighborhood BartenderClick Here for the latest Thanksgiving adult bevvies and gorgeously staged photographs DANA'S KETO KORNER:Cauliflower Mash Pie CrustPie FillingListen to “Dana’s Keto Korner” and all of Jeff’s other one-of-a-kind tunesClick HERE for Miracle Blend...the seasoning most Mauro’s can’t live without 

Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multiple infectious diseases. However, multidiscipline research strongly suggests that inflammation is also closely linked with a broad range of noninfectious diseases. The critical aspects of the interplay between inflammation and disease may well be the key to development of a new generation of drugs to treat previously untreatable diseases, sparking a flurry of biotech research and development in the field. At the vanguard of this new drug development, 180 Life Sciences Corp. (NASDAQ: KBLM) is driving groundbreaking studies in clinical programs aimed at developing novel therapeutics that address distinct areas of inflammation, finally offering hope for vast unmet medical needs in inflammatory diseases, fibrosis, pain and more. Amgen Inc. (NASDAQ: AMGN) acquired the anti-inflammatory drug Enbrel for $4.8 billion in 2018 and, in conjunction with AbbVie Inc. (NYSE: ABBV) and others, is testing anti-inflammatory drugs in a joint COVID-19 study. Actemra, an anti-inflammatory arthritis drug from Roche Holding Ltd. (OTCQX: RHHBY) previously failed to meet its primary endpoint in earlier COVID trials. Johnson & Johnson (NYSE: JNJ) now owns Remicade, which was developed by the current management of 180 Life Sciences, the first tumor necrosis factor-α (TNF) inhibitor and one of the top anti-inflammatory drugs in the world with over $5 billion in sales in 2019 alone.

Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multiple infectious diseases. However, multidiscipline research strongly suggests that inflammation is also closely linked with a broad range of noninfectious diseases. The critical aspects of the interplay between inflammation and disease may well be the key to development of a new generation of drugs to treat previously untreatable diseases, sparking a flurry of biotech research and development in the field. At the vanguard of this new drug development, 180 Life Sciences Corp. (NASDAQ: KBLM) is driving groundbreaking studies in clinical programs aimed at developing novel therapeutics that address distinct areas of inflammation, finally offering hope for vast unmet medical needs in inflammatory diseases, fibrosis, pain and more. Amgen Inc. (NASDAQ: AMGN) acquired the anti-inflammatory drug Enbrel for $4.8 billion in 2018 and, in conjunction with AbbVie Inc. (NYSE: ABBV) and others, is testing anti-inflammatory drugs in a joint COVID-19 study. Actemra, an anti-inflammatory arthritis drug from Roche Holding Ltd. (OTCQX: RHHBY) previously failed to meet its primary endpoint in earlier COVID trials. Johnson & Johnson (NYSE: JNJ) now owns Remicade, which was developed by the current management of 180 Life Sciences, the first tumor necrosis factor-α (TNF) inhibitor and one of the top anti-inflammatory drugs in the world with over $5 billion in sales in 2019 alone.

Our APRN Alex De Oliveira talks about her experience with Enbrel.

Dr. John Young gives an update on Enbrel and what patients are saying.

Hello, and welcome to this week's episode of The Ankylosing Spondylitis Podcast. I hope everyone is doing fantastic. This week's message is all about ways to distress yourself and you know how, to hopefully put yourself in a better position with your Ankylosing Spondylitis and your mental state.  This last week has been a bit of a challenge as my family moves through the one year anniversary of my father's passing. So you know, kind of some stressful items dealing with, thinking about, and I started looking and thinking what are ways that I can help myself to feel better, to move through this at an easier pace. I did turn to some meditation to help with the process just to really calm my mind and then look at some pictures and things like that. But how do I carry this forward for Ankylosing Spondylitis when it's not some kind of major anniversary but just in the day to day life, that we deal with having Ankylosing Spondylitis always present.  So I came across this article that was titled De-Stress with AS: 10 Strategies to Ease Your Mind(link at end of show notes). And I thought, you know what I'll read through them and there's a lot of really good information in it. As we all know, stress can trigger a lot of things. But for Ankylosing Spondylitis, the worst thing that we can get from stress is a flare, because we don't know how long that flare is going to last. And sometimes we can control it with medication and other times it runs amok and it's just over the top and we have no ability to rein it in until it decides it wants to stop. That alone is enough to try and keep stress at bay and it's really something we want to focus on as much as possible. There are many ways to de-stress you know, including properly treating your AS, practicing some relaxation techniques, talking to someone or just finding joy in a favorite hobby or extracurricular activity. So you may experience stress, you know, for multiple reasons, if you have Ankylosing Spondylitis with all the stuff going on right now with the COVID around the world, it could be financial health, all sorts of things are going on that can cause stress and lead to flares. Stress can lead to AS flares as I said, by creating tension in your body and triggering a response from your immune system. And once that happens, again, it's run amok and we don't have any easy way to control it. We can, again use medications to help to reel it in, but you know, that may or may not work. So what we want to do is proactively try to reduce stress, which may help to calm your mind and reduce or prevent additional ankylosing spondylitis symptoms. So, you know, try some of these methods.  Number one, Stick to Your Treatment Plan. One critical factor for managing Ankylosing Spondylitis is to stick with what the doctor recommended to you. This generally can help to reduce flares, not all the time, but it can help to reduce flares. And maybe that can help to alleviate some stress. So they provided a checklist of things and your treatment plan may include checking in with your doctor regularly, seeing a physical therapist, or similar medical professional, staying active and eating a healthy diet, taking medications as directed, especially during flares, resting when needed, and avoiding smoking. Now, most of those I've done for pretty much my whole life. I never smoked, resting you know, when you're a young guy, you go, go, go, go and same with people that everybody else when you're young, you just go like crazy. So you get as much rest as you can and you just deal with it that way. Now, taking medications is, in my opinion, very important. When I was younger, there were no biologics and when I got to point where I could take them the type Humira and Enbrel didn't work long term for me. So that was something that it wasn't until about three years ago that I was prescribed a different medication, a biologic Cosentyx that worked great for me. What worked for everybody, I... Support this podcast

Dr. John Young discusses the use of Enbrel on children with Down Syndrome

Leslie Gray Robbins is a mom of two, certified health coach, motivational speaker, voiceover actor, published author, and a Cancer Thriver. She is hopeful that her story can help inspire others on the cancer journey to consider all options and stand in their truth.She penned her first book with her daughter Addison Baily Robbins, then 8 years old. What Makes A Family? is a children's picture book that focuses on the many ways that families are created, and can be found at Barnes & Noble and on Amazon.Are you living your healthiest and happiest life? Leslie can guide you in making subtle changes in your everyday life, helping you reach your personal goals, and be your BEST self. To learn more about this side of Leslie, please visit http://balancedlifehealthyyou.comIn addition to being a health coach and helping people improve their lives, Leslie is also a professional voiceover artist. She has had the pleasure of working with esteemed clients such as Sargento, Ghirardelli Chocolates, Capri Sun, Travelocity, Enbrel, Hampton Inn, and Blue Cross Blue Shield, among others - view her acting website atwww.LeslieGrayRobbins.comLeslie continues to sing whenever she gets the chance and is very grateful for her partner in crime, Carrie Marcotte, who helped created the group TAKE TWO Singers. www.TakeTwoSingers.comLeslie also created the a cappella group, Route 66 in 1994, and continues to make music with these amazing ladies whenever possible! Check out the tight harmonies here: https://www.facebook.com/route66sings/Your world stops when you hear those 3 words, "You have cancer". From the moment you are given that diagnosis, you have a choice: Will you allow fear to lead you, or will you take a deep breath and find your inner strength?This is the detailed story of my personal journey of healing from triple negative breast cancer, a rare and aggressive type of cancer. I quickly decided that I wanted to avoid the harmful conventional approaches of chemotherapy and radiation, and instead focus on the many holistic options available.My goal is to empower other Cancer Thrivers by sharing what I've learned along the way, and in the process, inspire them to lead the charge back to health!

Erik Lindbergh, a commercial pilot and certified flight instructor, is the grandson of Charles and Anne Lindbergh and son of Jon Lindbergh and Barbara Robbins. As 2002 marks the 75th anniversary of his grandfather’s Spirit of St. Louis transatlantic flight, Erik Lindbergh will recreate this 1927 milestone, illustrating the human spirit’s ability to dream, innovate and achieve one’s goals against many odds.   Though he leads an active lifestyle, Erik also suffers from rheumatoid arthritis (RA), a progressive autoimmune disease marked by pain, tenderness, and inflammation of the joints, that nearly caused him to give up his passion for aviation when he was diagnosed at the young age of 21. RA crippled Erik for 15 years and only recently has he been active again. During his worst years with RA, Erik was forced to use a cane due to the severe pain that made it almost impossible for him to walk. Today, with the help of a breakthrough biotech drug, Enbrel, Erik has his life back and is in pursuit of his dreams. Using his experience with RA, he now serves as a spokesperson for the Arthritis Foundation, working to educate others about RA.   A graduate of Emery Aviation College where he received his Aeronautical Science degree, Erik serves as a Trustee and Vice President of the X PRIZE Foundation, a non-profit organization that stimulates the creation of a new generation of launch vehicles designed to carry passengers into space. The X PRIZE is fashioned after the Orteig Prize, the aviation incentive prize won by Charles Lindbergh’s transatlantic flight in 1927, which created the now $250 billion aviation industry.   Erik is also a Director of the Lindbergh Foundation, a non-profit organization dedicated to furthering his grandparents belief in creating a balance between technological advancement and environmental preservation. The Foundation promotes gives grants, does educational programs and gives the Lindbergh award each year for work dedicated to “Balance” concept. Aside from aviation, Erik is an artist and owner of Lindbergh Woodworks, which creates unique furniture and wood sculptures. He is known for his sculptures of rustic planets, spacecraft and aircraft within the community of astronomy and aviation.

Cory Rubin is a Board-Certified Dermatologist practicing at the Michigan Dermatology Institute in Waterford, Michigan. He is the founder and medical director of the practice, and is on staff with several large health systems in Michigan including Ascension/St John-Providence, Beaumont-Royal Oak, DMC Huron Valley-Sinai, McLaren-Oakland and St Joseph-Oakland hospitals. His medical school education was completed at Thomas Jefferson University in Philadelphia and his dermatology residency training was performed at the University of Michigan in Ann Arbor. He has a passion for complex medical dermatology and professional skin care. When not practicing, he is a proud father, happy husband and avid ice hockey player. Instagram links https://www.instagram.com/@208SkinDoc https://www.instagram.com/@treasurevalleyderm https://www.instagram.com/@michiganderminstitute If you think you may have psoriasis and would like to seek out a dermatologist in your area please visit https://find-a-derm.aad.org/ to locate a board certified dermatologist in your area.  For additional resources for patients with psoriais please visit https://www.psoriasis.org/ or https://dermatologyboise.com/What-We-Treat/Psoriasis Oral medications discussed included methotrexate as well as Otezla https://www.otezla.com/ The biologic injectable medications we discussed are listed here as well according to their class, and otherwise in no particular order.  TNF-inhibitors Humira https://www.humira.com/ Enbrel https://www.enbrel.com/ Cimzia https://www.cimzia.com/ Remicade https://www.remicade.com/ IL-17 inhibitors/receptor blockers Cosentyx https://www.cosentyx.com/ Taltz https://www.taltz.com/ Siliq https://www.siliq.com/ IL-23 inhibitors Ilumya https://www.ilumya.com/ Tremfya https://www.tremfya.com/ Skyrizi https://www.skyrizi.com/ IL-12/23 inhibitor Stelara https://www.stelarainfo.com/ If you have found this information helpful please consider leaving us a 5-star review on Apple Podcasts or wherever you get your podcasts.

Hello, and welcome to this week's episode of The Ankylosing Spondylitis Podcast. I hope this show finds everybody doing well. In today's show, I want to look at the relationship between your microbiome and Ankylosing Spondylitis. The reason for this came about from looking at a few items online and in some of the forums on Facebook. I was seeing one particular thread I believe an example that there was a number of people giving definitive, this is how I got Ankylosing Spondylitis. This caused my Ankylosing Spondylitis and that might have triggered a flare that brought the Ankylosing Spondylitis to your attention, or made you notice some of the symptoms that made you look further into what was causing them. But at this time, there really is nothing that I've ever found that says the doctors can pinpoint to this one exact reason as to why you got Ankylosing Spondylitis. No, there are some different contributing factors and there are some items that again, may have happened that triggered the domino to happen and and Ankylosing Spondylitis to finally come to life. There's nothing that at this time, they know, this is what exactly triggered anybody's Ankylosing Spondylitis. And that's what's really frustrating for a lot of us with the disease, is that we all present differently. We all get different symptoms, different reactions to medications. And if you listen to my episode a few back with Dr. Fox (Episode 42), he said there are some tests coming down the road that could help to better pinpoint which biologics you'll respond to better versus others. And that way, it's not such a guessing game like there is now with biologics where it's like, well take Enbrel if it doesn't work take Humira, if it doesn't work, take this one. It might take you four, five, or six until you find one that works. And if they have a way to narrow that down to one or two, that in of itself would be a great start to treating Ankylosing Spondylitis. The real big breakthrough is going to come when they can figure out what underlying symptoms make you susceptible to having it at some point in the future. One of those things is the gene, HLA-B27. Many people have that gene and it doesn't mean that if you have it, you will develop Ankylosing Spondylitis. Because there's people that don't have it, that develop Ankylosing Spondylitis. So it's just one of those factors to look at. So I happened to be looking around on ankylosingspondylitis.net, which is a fantastic resource, that if you're not using it you should be. People with Ankylosing Spondylitis write many of the articles and the editorial team writes many. I encourage you to head over, it's just a fantastic resource. And it got me thinking, I found this article, which is where I tell the show about the relationship between the microbiome and Ankylosing Spondylitis. And I thought it was really interesting. I've also saw a lot of people coming onto the forum saying, I'm brand new. I need to learn. Where do I start? What do I do? So this is something that might be a good spot to start to think about as you try to develop your game plan for dealing with Ankylosing Spondylitis. What we know is that about 40 years ago, researchers found out that people with HLA-B27 are much more likely to get Ankylosing Spondylitis.  HLA-B27 is a genetic trait associated with the immune system and the inflammatory conditions like Ankylosing Spondylitis. Well, scientists still don't know why. There is connection between Ankylosing Spondylitis and HLA-B27. They continue to study that relationship, and the potential link to help find further treatments for the condition of, of ALS and, and potentially other items. So, one of the areas that is being researched and I want to look at some more, and this is the microbiome. What is the microbiome? Well, all of us have trillions of bacteria living, you know, in us and on us on our bodies, you know, in our bodies, and this collection of bacteria is called your microbiome. Most Support this podcast

Getting Enough Calcium; Coconut/Avocado Oil Potato Chips; Booze while Keto affecting Gut Health; Pumpkin Seed Oil; Gluten and Thyroiditis; and current event: students & families’ reaction to schools in “meat-loving rural Brazil” going vegan. Make your health an act of rebellion and join the community here. Please Subscribe and Review: Apple Podcasts | RSS   This episode is sponsored by Elemental Labs and their electrolyte drink mix LMNT Recharge. Download a copy of the transcript here (PDF)   Show Notes: News topic du jour https://www.washingtonpost.com/world/schools-in-meat-loving-rural-brazil-went-vegan-the-community-revolted/2019/11/03/0ab77928-ec56-11e9-9306-47cb0324fd44_story.html Schools in meat-loving rural Brazil went vegan. The community revolted. 1. Calcium [14:05] Erica says Hi Robb! I first want to say thank you so much for the wealth of knowledge you share. Your book,The Paleo Solution, helped me get off Enbrel which I was taking for 13 years for Rheumatoid Arthritis. I’ve been medication and symptom free for a year just by following a Paleo/keto diet and I don’t ever plan on going back to my old life of processed foods, joint pain, and weekly injections of Enbrel. However, I am concerned about my calcium intake. Dairy and beans flare up my arthritis symptoms and I don’t digest leafy greens well at all. I know sardines are a good source of calcium, but I just can’t stomach them.

In this episode, I look at some basics of biologics like Enbrel, Humira, Cosentyx and my experience with those items. There are numerous biologics available to patients with Ankylosing Spondylitis and the correct one for you may take some time to find as you try different options and your rheumatologist tracks your health.   Below are some links to articles that discuss biologics in very basic terms.   https://www.healthline.com/health/beyond-back-pain-with-as/will-biologics-work%234 (https://www.healthline.com/health/beyond-back-pain-with-as/will-biologics-work#4) https://www.healthline.com/health/beyond-back-pain-with-as/biologic-science%234 (https://www.healthline.com/health/beyond-back-pain-with-as/biologic-science#4) https://www.healthline.com/health/beyond-back-pain-with-as/biologic-options%231 (https://www.healthline.com/health/beyond-back-pain-with-as/biologic-options#1) Support this podcast

David Rosenthal is one of the nation's top voice over coaches, as well as the founder of InternetVoiceCoach.com. He has 20 years of teaching and voice over coaching experience and has helped many people get their start or further their career in the industry. He is also the Co-Owner of the Global Voice Acting Academy or GVAA. As an actor, David has been cast on-camera in over 60 national television commercials, including Toyota, Pillsbury, Citibank, Sprint, Enbrel, True Value Hardware, Pizza Hut, and Alka Seltzer. He was also the host of UPN’s Rave Reviews for three years. As a voice over talent, David has over 1000 voice over credits to his name in all areas of the industry, including almost 70 video games. He especially loves to coach character and commercial voice over. Aside from Voiceover and his photography hobbies, David Toback serves as the Chief Operations Officer for the Global Voice Acting Academy (GVAA), managing the day-to-day operations. David joined the team in 2016 after co-creating the GVAA Rate Guide. Originally a student, he was fortunate enough to be mentored by owner and founder, Cristina Milizia. After needing rate advice and getting resources from Cristina, David created a rate guide that became the inspiration for and genesis of the GVAA Rate Guide. Shortly thereafter, he joined the staff in a finance and operations capacity. Since that time, he’s become an integral part of the organization’s growth and development, and now serves as the Chief Operations Officer managing all business operations of the GVAA. David found an outlet to use his business and marketing skills to help people learn and pursue their dreams while making a meaningful impact to an ever growing and changing industry. The experiences he’s been afforded and lessons he’s learned in his time at the GVAA have been invaluable to his development as a person and actor and have served to improve his voiceover business. He couldn’t be more grateful and proud. You can visit the GVAA website at https://globalvoiceacademy.com/

The Washington Post recently reported that Pfizer buried data that one of their drugs, Enbrel (etanercept), might prevent Alzheimer’s disease. While some researchers expressed outrage over this decision, others argued Pfizer's findings were barely worth talking about. We speak to Hank Greely, a Stanford law professor about whether pharma has a moral obligation to share research findings with the public, plus what you should know when sharing your genetic data with testing companies.

Volvemos a la carga, con un mes bastante más interesante que el infame mes de Mayo. Al principio del episodio tenemos la sospecha de que Abraham había vuelto a las andadas quedándose dormido, pero afortunadamente es solo uns sospecha, simplemente el hombre se retrasó. El contenido de este episodio es el siguiente: 73 es el único número primo de Sheldon. El caso de Pfizer y Enbrel. Dos nuevos exoplanetas alrededor de Teegarden Los Astrobee ya vuelan solos. Como combatir el cáncer con las Matemáticas. Una gran masa incrustada en la Luna. Los 737 Max aparcados en un parking de empleados. Nueva terapia personalizada para el cáncer de páncreas Margarita Salas inventora del año 2019 según la EPO. Posibilidad de salvar al gato de Schrödinger. Repaso a las efemérides más importantes del mes de Junio. Disfrutad de este nuevo pograma!!!

ASCO was a little uneventful and the Washington Post seems to be trying to make something out of nothing

Links in show notes: DementiaSherpa.com/bonus-episode-the-pfizer-story. In 2015, Pfizer researchers discovered their own anti-inflammatory drug, Enbrel, appeared to reduce the risk of Alzheimer's disease by 64%. Last Wednesday, four years later, the rest of us found out about it. Phil and I discuss in this bonus episode.  

Zona Vip: https://easysmartech.com/vip/ Canal de Telegram: https://t.me/easysmartech Google será investigada por monopolio en Estados Unidos. https://easysmartech.com/google-sera-investigada-por-monopolio-en-estados-unidos/ Huawei podría estar bajando la producción de sus dispositivos. https://easysmartech.com/huawei-podria-estar-bajando-la-produccion-de-sus-dispositivos/ El medicamento Enbrel podría trata el Alzheimer y la farmacéutica Pfizer lo ocultó. https://easysmartech.com/el-medicamento-enbrel-podria-tratar-el-alzheimer-y-la-farmaceutica-pfizer-lo-oculto/ Las noticias falsas dejarán de ser falsas próximamente en Twitter. https://easysmartech.com/las-noticias-falsas-dejaran-de-ser-falsas-proximamente-en-twitter/ El comienzo de la ultra automatización con RoboRaise del MIT. Un robot que copia el movimiento de tus músculos. https://easysmartech.com/el-comienzo-de-la-ultra-automatizacion-con-roboraise-del-mit-un-robot-que-copia-el-movimiento-de-tus-musculos/ El iPad ya es un portátil iOS 13. https://www.ivoox.com/ipad-ya-es-portatil-ios-13-audios-mp3_rf_36632336_1.html Vídeo sobre cómo instalar iOS 13. https://www.youtube.com/watch?v=Gs_Y34gkYjM REDES SOCIALES: https://www.instagram.com/easysmartech @easysmartech https://easysmartech.com https://www.youtube.com/c/easysmarttech --- Send in a voice message: https://anchor.fm/marm1978/message

- Jackie was first diagnosed with RA in 2016 and the pain was devastating - After a difficult diagnosing process she started methotrexate and Enbrel, and after 8 months things weren't changed much - In the next 6 months she went through some cumbersome insurance mechanisms and eventually was eligible for Rituxan - She started Rituxan infusions while dropping Enbrel and keeping methotrexate, and after a couple of months she was feeling better - In the meantime she found the Paddison Program while searching through the internet, and decided to start with it as well - Then her insurance company refused to support other infusions of Rituxan and she decided to proceed with the Program anyway - Jackie is now only on a minimal dose of Methotrexate and has added Bikram yoga to progress her health even further!

- Ted has been diagnosed with RA in 2004 after an episode of acute knee pain - She immediately started methotrexate and prednisone at a very high dosage - The pain started also in the ankle, and several exams didn't shed light on the situation - Then she started Enbrel and it was a big relief compared to the previous levels of pain - But with the prolonged use came some infections as a side effect, and Ted started taking antibiotics - After stopping Enbrel for some time, it did stop working and she switched to other biologics, which gave other nasty side effects - She then found the Paddison Program and after 24 hours the pain was gone and she was able to walk freely - She has made radical changes in her diet and the results are great

- After being diagnosed with RA at 21, Tom started taking many different medications - He started with Celebrex and after 4 months he added Methotrexate, which had heavy side effects - Enbrel was also added to the mix and initially it helped with the symptoms - After about 8 months Enbrel started to lose its effect, and switching to Orencia didn't help as well - After having stopped Methotrexate Tom wasn't able to start again with it and began taking Rituximab - Rituximab started working and in the meantime, Tom went on the Paddison Program - His change in diet and lifestyle following the Program helped him reduce the side effects of the drug to a great extent - At that time he was still taking Celebrex and prednisone, but thanks to his new diet he eventually stopped both - He's now on his journey to recovery and progressing every day

- At the age of 30 Carolyn started having symptoms - swollen knees, fatigue and a lot of pain overall - It took six years for her to be diagnosed with Psoriatic Arthritis - After being diagnosed, she started going through different medications - sulfasalazine, Prednisone, Plaquenil - She went on Methotrexate for a brief period of time, but it made her extremely sick - Two years ago she started with Enbrel, which gave her the least side effects - But after about one year the symptoms started to come out again - Carolyn then found the Paddison Program and after 2 days the swelling was gone - She's now on the Program and her condition is improving everyday - She is now a member of Paddison Program Support to get assistance with her next health objectives

- Jackie organized an event on the Isle of Man to raise awareness about autoimmune diseases - She invited Katy as a speaker and she told her story to the audience - Before her first birthday, Katy was diagnosed with juvenile rheumatoid arthritis - She grew up having to learn to live with chronic pain and a sense of hopelessness - In 2000 she switched from methotrexate to Enbrel, which helped a lot, but the pain never went away - In 2010 Katy started a job as a dietary aide, but she needed pain killers to get by - She entered a spiral of depression until she found a video of Clint - She binge watched all his podcast episodes and the next day was her day 1 on the Program - After a year and a half she feels more energized than ever and getting stronger every day

We discuss how: - Johanna has been experiencing swellings and pain for 4 years - She's been on Methotrexate, Sulfasalazine ,Prednisone and also Apremilast for about two years with tremendous side effects - Within 2 years all other options failed and she started Enbrel, but it didn't bring any stable improvement - In November 2017, just when she hit her all-time low, she found the Paddison Program - Within 3 1/2 months her energy is back and she's pain-free and drug-free - Here hair is grown back, after she lost about 40 percent of it due to Methotrexate - Bikram Yoga has also turned out to be a great energy source - She found great inspiration and support in the Program's material and community

In this episode: Medical News (1:50) – Link between nighttime light exposure and depression Preventative Medicine Tip (5:55) – Diabetes Screening Recommendations (https://www.uspreventiveservicestaskforce.org/) Guest Interview (13:50) – Ariana Grossu, Outreach Advisor at the Office for Civil Rights at the US Department of Health & Human Services, discusses the newest HHS initiative – the Conscience and Religious Freedom Division – and what current and potential policies protect health care workers from having to violate their conscience in their practice. For more information visit: www.hhs.gov/conscience Medical Trivia (Answer at 39:15) – According to MedScape.com, which of these prescription medications garnered the most sales in 2016 - at $13.6 billion? 1. Enbrel (etanercept) 2. Harvoni (ledipasvir sofosbuvir) 3. Lantus Solostar (insulin glargine injection) 4. Humira (Adalimunab) 5. Remicade (infliximab) Listener Question (42:30) – If I took birth control when I was younger before I knew about the harmful effects, is there anything I can do now to decrease my risk of getting cancer? Medicine You Need to Know (45:20) – Catholic Witness in Healthcare editor Dr. John Travaline discusses how St. Padre Pio’s vision for authentic Catholic healthcare is coming to the United States ------ Live: www.redeemerradio.com Follow us on Facebook: @DoctorDoctorShow Submit your question(s): Text (Holy Cross College text line) - 260-436-9598 Online - www.RedeemerRadio.com/Doctor E-mail - Doctor@RedeemerRadio.com Subscribe to the Podcast: iTunes | Google Play | SoundCloud | RSS

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I’m looking forward to sharing with you some of our community’s questions that have come in over the past few weeks…  Let’s get started! Cristi: Hi Dr. Cabral, I apprecate the work you do more than you know. I ordered the daily protocol package to try with my husband and maybe kids too, but I do have other questions. Mostly, I’m wondering which supplements we’re currently taking would still be necessary, and in what amounts. For example, if I want to take additional vitamin D because it’s winter and we do live in a suburb of Boston as well, would I need more K2 than is included in the daily formula? Currently we take D3 with K2, and I know there is K2 in the formula, but is it enough to counterbalance extra D3? I also use collagen peptides on a daily basis as my protein in the morning. If I want to continue that, will that be too much protein in addition to the shake? The collagen peptides are listed as having 20 g of protein in two scoops, but I have also heard that this is not a complete protein. I do like the benefits of the collagen peptides and bone broth when I do not have the peptides, so I’m just wondering how to work this in to my regimen without getting excessive protein. I also take curcumin, Ashwaganda, and glucosamine condroitin. I do not think these are included in either the fruit and vegetable blend or the shake, so I believe I would continue these for joint health and stress? We also take a grapeseed extract from Pure synergy, but I see that is included in one of the blends. I’m assuming that would be redundant then? I am looking to cut down on the number of supplements we take and streamline a little bit. In addition, if we are going to do this for the whole family, it will end up costing a bit. I wish we could afford a consult or functional medicine testing right now, but we cannot. If more information is helpful, I take Synthroid for low thyroid, but I now have a very low-dose .88 MCG. My husband is on no medications, but he has untreated sleep apnea. I have many allergies, so I would like to get testing and try the allergy protocol when I can afford it. I exercise daily, and I am at a healthy weight, and my husband has recently lost quite a bit of weight, and is at a healthy weight too. He does not exercise, but he is a contractor, and his job has him moving all the time. We eat what might be called a Paleo diet, but with emphasis on vegetables, much as you recommend. I, in particular, have always tried to optimize my nutrition, and at age 43, and I am hoping to tweak a few things and figure out how to take care of my allergies without taking Claritin daily, why I get headaches, and why my digestive system seems very sensitive sometimes. For various reasons, life has been very high stress for a long time. We live in a suburb of Boston, and it is my dream to one day visit your wellness center. I am so sorry for the long question! I understand if it’s too much. Thanks, Cristi   Jackie: Hi Dr. Cabral, I started seeing a ND about three years ago after I attended a gym in SF. I started having symptoms of adrenal fatigue and I started noticing I wasn't digesting food well and had high cortisol levels. I took food panels, conducted blood tests, acupuncture and tried some elimination diets. All of this aided in the healing of my gut as well, I did find out I had leaky gut from my food panels. I recently visited the same gym earlier this year that had sparked some of these similar symptoms I had previously experienced. I am thinking my body is having some sort of histamine response or possibly an allergy to toxic mold. I have done more blood work, new food panels and other elimination diets as my current ND and I think it may be food and environmental. I am also wondering if it is something in my apartment. My symptoms are sinus pressure, headaches, ear pressure/wax build up, eye strain and focus, I sometimes get a little light headed or dizzy standing up, mucus, post nasal drip, my chest is tight and I have been wheezing a little bit. Some days are better than others. I wanted to get another opinion and advice on what next steps should be. Thank you!   Anonymous: I am on Day 31 of the CBO and it is going great and relatively easy. Unfortunately I just got a herpes (HSV II) outbreak and I have listened to your previous podcasts on Herpes and remedies. However, the Super Lysine, I cannot take because it has garlic and I can't have the Apple Cider Vinegar because of being on the CBO. I just upped my zinc and I will add magnesium spray and meditation, etc. Fortunately, my outbreaks are mild, but they hurt my mind and soul! I had the HSV II confirmed by a blood test when I was pregnant 3 years ago. It is something that definitely has changed my intimacy with my husband (he does not fear it at all) but I know there can be asymptomatic outbreaks and it makes me paranoid. I went a year without any outbreak and now I'm getting them every couple of months. Sleep is still a little elusive with a toddler, so maybe it's lack of sleep causing the stress. Or whenever I try to add running to my workouts, it seems to cause an outbreak. I was adding two days a week of 30 minute jogs and two weeks after that, I get an outbreak. Maybe running just is not for me? I was trying to add the 30 minutes of straight cardio after hearing your podcast on cardio. I also notice an outbreak after I get extremely angry about something, which did just happen. I eat super healthy and I do not drink alcohol (I have had maybe 4 glasses of wine this past year - pretty good for a first time mom!!), I do indulge in dark chocolate daily. Although, being on the CBO, I just started having 100% cacao after the initial 21 days. In one of your podcasts on herpes you say you've helped people fully eliminate (or cause dormancy) with herpes. I could really use this in my life, especially with wanting to have another child and not wanting to have this get in the way of that process or the delivery process. ******To do further work in an aim to fully eliminate the virus, do I need to schedule a consultation with you?***** Thank you as ALWAYS!   Dave: Good Afternoon A friend forwarded your podcast to me awhile ago. I try and read the ones that pertain to me but somewhere along the way I might have missed anything that deals with Arthritis Diets. Two and a half months after surgery in December 2015, psoriatic arthritis hit me in my feet and osteo-arthritis in my knees. Before my surgery I was walking the golf course carrying my bag with no issues. After surgery I became a cripple. I couldn’t get up from a chair, climb stairs let alone swing a club. I have sorely missed golf for two years now. I am 68 years old and 6 weeks ago I read an article on the importance of diet. (duh) The article did not specifically deals with diet concerning arthritis so I did some more research on foods that cause inflammation. I eliminated red meat, dairy, sugar and processed foods. I stick to veggies, fruit and fish. I do cheat on occasion and treat myself to chicken but that is just for some variety. Organic as much as I can find. Since I really enjoy your approach to life from every angle I would appreciate your thoughts and help to get me back on the golf course again. The last 3 weeks I have noticed a marked improvement which I am attributing to the “new” diet routine. I also do some Physio, CBD and an occasional rum&coke. Enbrel and methotrexate are helping with the psoriatic feet. I wish you and your family a wonderful Christmas   Mari: You have been so helpful throughout my health journey. I have noticed within the past year that either the day before and when I am already menstrating that I get these intense headaches that seem like sinus headaches. I get really bad neck pain, ear pain, temple throbbing and I get really moody as well. I have deep pains under my eyes and around my sinus area. There just feels like so much pressure and tension in my ears and my face. I get extremely irritable a few days before and during. I am on birth control and plan to come off soon and am hoping this doesn’t get worse by coming off. Thank you for tuning into this weekend’s Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes & Resources: http://StephenCabral.com/723 - - - Get Your Question Answered: http://StephenCabral.com/askcabral      

S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases.

In this episode you will learn: Jyoti's difficult journey so far How Bikram yoga is still the best anti-RA exercise How Prednsione and Enbrel cannot hold the disease at bay The emotional trauma that comes with RA The path forward How we need support Decisions in trying to start a family whilst on heavy medications  

You'll learn in this podcast from Walter how he experienced: - Severe RA that had him bedridden - Methotrexate fatigue - Enbrel "hang over" side effects - Humira caused all of his RA to return again - Xeljanz caused massive nausea and constipation - The dangers of antibiotic overuse which may lead to RA onset - How the nasal passage is a great indicator of food sensitivities - And how Walter is doing great on the Paddison Program for RA which has no side effects

Bird Rock Bio, a small, San Diego-based biotech, is planning to take aim at some of the biggest biologics on the market with an antibody in development to treat rheumatoid arthritis that it says it expects to market at an annual cost of just $2,000 a year. That compares to around $30,000 a year for drugs such as Humira, Remicade, and Enbrel that are TNF inhibitors. The experimental therapeutic known as Gerilimzumab targets IL-6. We spoke to Paul Grayson, president and CEO of Bird Rock Bio about the company, the benefits of targeting IL-6, and how the company expects to be able to offer the drug at such a disruptive price point.

Today in FirstWord:

This podcast is on Amgen Enbrel with A Biological Place to Start Faculty with Product Theater with Firas Hougeir, MD and was recorded at the 2013 SDPA Fall Conference in Atlanta.

Hear about Enbrel in this Product Theater recorded at the SPDA 2013 Summer Conference in St. Louis.

Today in FirstWord:

This was audio was recorded at the 2012 Summer conference in Seattle Washington

This was recorded at the 2011 Fall Conference in Orlando Florida